Polaris Partners

Polaris Partners is a venture capital specializing in investments in all company lifecycle stages including earliest startup, seed, early stage, mid venture, late venture, first round investments, emerging growth, expansion, growth capital, liquidity, and minority growth equity investments. It typically invests in technology, energy, healthcare, life sciences, business services, and consumer sectors. Within technology the firm invests in seed, early stage, and growth equity, in the cloud infrastructure; SaaS; software; e-commerce; consumer Internet; data sciences, marketplaces, broadband telecommunication services, telecommunication software, communications Equipment distribution, network software, wireless networking equipment, communication equipment, and digital media and entertainment sectors. Within healthcare, it invests in seeding, early venture, and growth equity, in the biotech and pharmaceuticals; medical devices, diagnostics, medical device research equipment, therapeutic devices, drug delivery technologies, gene research and development, protein and genome sequence products, life sciences and tool service, healthcare services and products, digital healthcare; and healthcare IT sectors. Within consumer, the firm invests in early to seed, and growth equity in e-commerce, consumer services, media, entertainment services, food and beverages, and consumer technology sectors. The firm prefers to invest in portfolio companies based in North America with a focus the United States; Canada, Caribbean, Central America and Mexico and can selectively invest in Asia and Europe with a focus on Ireland. It typically invests between $0.5 million and $150 million in portfolio companies with a EBITDA between $4 million and $25 million. It takes minority and majority stakes in companies. The firm generally acts as a lead or co-lead investor. Polaris Partners was founded in 1996 and is based in Boston, Massachusetts with additional offices in Dublin, Ireland; San Francisco, California; and Waltham, Massachusetts.

Steve Arnold

Founding Partner Emeritus

David Barrett

Managing General Partner

Dave Barrett

Partner

Marissa Bertorelli

Principal

JB

Jack Burke

Associate

Alexandra Cantley

Partner

Darren Carroll

Partner

Brian Chee

Partner

Sabrina Chiasson

VP

Isaac Ciechanover

Partner

George Conrades

Venture Partner, Venture Partner Emeritus and Partner Emeritus

Alan Crane

Entrepreneur Partner

JA

Jonathan A. Flint

Founding Partner

Peter A. Flint

Venture Partner

Jon Flint

Partner

JF

Jason Franklyn

Associate

Harold Friedman

CFO

Brendan Hannigan

Entrepreneur Partner

Mark Jacobson

VP

RK

Rahul Kakkar

Entrepreneur Partner

TJ

Timothy J. Kilgallon

CEO-in-Residence

Pat Kinsel

Venture Partner

Dan Lombard

Partner

EM

Ellie McGuire

Partner

TM

Terry McGuire

Partner

Pat Mulach

Associate

Amir Nashat

Partner

Jeff Del Presto

VP

Connor Ryan

Senior Associate

Amy Schulman

Partner

Gary Swart

Partner

Sharif Vakili

Associate

JW

Jim Weinstein

Entrepreneur Partner

Bryce Youngren

Partner

joanna zesiger

Director of Finance

659 past transactions

OM1, Inc.

Series C in 2019
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

amunix

Series A in 2020
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Impinj, Inc.

Series B in 2002
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Vhoto

Seed Round in 2014
Founded by tech-startup veterans and based in the heart of Seattle, Vhoto is an iOS app that leverages the richness of HD video to capture and share life’s best highlights - which we call vhotos. Using machine learning and computer vision technology, Vhoto quickly and intelligently finds the best GIFs and photos from video all in the palm of your hand.

aTyr Pharma, Inc.

Series C in 2009
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Acceleron Pharma

Series C in 2007
Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

Microbia

Series B in 2000
Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Ember Technologies

Seed Round in 2001
Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Thirty Madison, Inc.

Series C in 2021
Thirty Madison, Inc., a digital health company, owns and operates web-based platforms for patients with hair loss, migraines, and other chronic conditions. It offers Keeps, a subscription-based online marketplace for over-the-counter medications for men’s hair loss prevention. The company also provides Cove, an online doctor visit and prescription service to treat migraine. In addition, it offers Evens that helps to treat acid reflux. Thirty Madison, Inc. was incorporated in 2016 and is headquartered in Astoria, New York.

Neumora Therapeutics

Series A in 2021
Neumora Therapeutics operates as a clinical-stage biotechnology company pioneering precision medicines for brain diseases through the integration of data science and neuroscience.

Avitide, Inc.

Series C in 2015
Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

Freenome, Inc.

Series A in 2017
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

HealthCentral

Post in 2008
The HealthCentral Network, Inc. owns and operates Web sites and multimedia affiliate properties that provide medical information, personalized tools and resources, and connections to a community of experts and patients. The company was formerly known as ChoiceMedia, Inc. The HealthCentral Network, Inc. was founded in 1999 and is headquartered in Arlington, Virginia.

Cushcraft Corp.

Seed Round in 1997
Cushcraft Corp. designs, develops, manufactures, and distributes antennas and other passive radio frequency (RF) products for broadband wireless, communications, and data connectivity solutions.

Life Line Screening of America, Ltd.

Private Equity Round in 2005
Life Line Screening of America, Ltd. provides community-based preventive health screening services in the United States and the United Kingdom. The company offers ultrasound, finger-stick blood, and limited electrocardiograph screenings. It provides screenings for stroke/carotid artery disease, abdominal aortic aneurysm, stroke/atrial fibrillation, peripheral arterial disease, heart disease risk, osteoporosis risk, elevated C-reactive protein, high cholesterol, type 2 diabetes, elevated liver enzymes, and chronic kidney disease. The company was founded in 1993 and is headquartered in Austin, Texas.

ARInsights, LLC

Venture Round in 2020
ARInsights, LLC develops cloud based analyst relationship management software solutions. The company offers a software as a service (SaaS) based platform, ARchitect, which provides relationship management and workflow modules for analyst relations. It also provides ARchitect event manager, ARchitect portal, ARchitect database, ARchitect Relationship Manager, ARchitect Emailer, ARchitect mobile application, ARchitect Reporting, ARchitect Analyst Grouping, and ARchitect Briefing Book tools and plug-ins. In addition, the company provides ServicePlus solutions for strategic planning, project support, administration, and operational assistance services. The company was founded in 2004 and is based in Sunny Isles Beach, Florida.

CAMP4 Therapeutics

Series A in 2021
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

Quartet Health, Inc.

Series A in 2015
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.

PMI BioPharma Solutions

Series A in 2021
PMI BioPharma Solutions is providing a comprehensive service offering to advance drug discovery, pharmaceutical development, and clinical manufacturing for the pharmaceutical and biotechnology industries. PMI BioPharma Solutions is uniquely positioned to support individual projects or to serve as an extension of its customers’ development teams. PMI BioPharma Solutions is planning to scale its manufacturing capabilities to support late-stage clinical and commercial liquid and lyophilized filling demand, to help support projects from clinical development to commercial launch.

BridgePoint Medical

Venture Round in 2009
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

PostRocket

Seed Round in 2012
PostRocket helps Facebook Page owners improve their performance on getting into their fans’ Newsfeeds - without any previous Edgerank knowledge required. Page owners follow daily recommendations tailored from our analysis of their own Insights data to achieve the best performance by optimizing for type, frequency, content and timing of the posts. Although our NFO algorithm is very raw and we have a ways to go still, our early tests have shown significant increase in the number of fans a post reaches - with some early testers averaging over 2x in fans reached in per post.

Tectonic Therapeutic

Series A in 2021
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.

Promedior

Series D in 2012
Promedior, Inc. a clinical-stage biotechnology company, develops therapeutics to treat rare fibrotic diseases, such as myelofibrosis and idiopathic pulmonary fibrosis; and retinal fibrovascular diseases, such as age related macular degeneration and diabetic retinopathy. Its portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein (rhPTX-2) formulated for intravenous injection; and PRM-167, a variant of rhPTX-2 developed for intravitreal delivery in retinal fibrovascular diseases. Promedior, Inc. was formerly known as Fibrotix, Inc. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of February 13, 2020, Promedior, Inc. operates as a subsidiary of Roche Holding AG.

PathAI

Series C in 2021
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Advion Inc.

Series B in 2002
Advion is a global company that offers a variety of systems and consumables for life science research. Its clientele is comprised of pharmaceutical companies, government life science research agencies, and universities. Advion provides a diverse portfolio of microfluidic and mass spec-based products for the life science industry. It was founded in 1993. The company is headquartered in New York, United States.

Adagio Therapeutics, Inc.

Series C in 2021
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Alector

Series E in 2018
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Adagio Therapeutics, Inc.

Series B in 2020
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Egnyte, Inc.

Series A in 2009
In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

amunix

Series B in 2021
Amunix Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops protein and peptide therapeutics products for cancer. It focuses on XTEN, a half-life extension platform; XPAT (XTENylated Protease-Activated T Cell Engager) platform using its XTEN technology to analyze protease activity in the tumor microenvironment; and Protease Triggered Immune Activator (ProTIA), an immuno-oncology therapeutic. The company caters to the academic, biotechnology, and pharmaceutical sectors. It has strategic partnerships with Janssen, Biogen-Idec, Noxxon, Baxalta, Ambrx, Seattle Genetics, and Versartis. The company was formerly known as Amunix, Inc. Amunix Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Mountain View, California.

Logentries

Series A in 2013
Logentries is a SaaS-delivered log management and analytics service, developed to make machine-generated log data easily accessible to developers, operations, and business analytics customers. While traditional log management and analytics solutions require advanced technical skills to use, and are costly to set-up, Logentries provides an accessible alternative for managing huge amounts of data, visualizing insights that matter, and sharing that information across the business. With more than 20,000 users in over 100 countries, Logentries is processing billions of events everyday.

Jnana

Series B in 2021
Jnana Therapeutics Inc. operates a drug discovery platform focused on solute carrier (SLC). The company is focusing on immunometabolism, lysosomal function, and mucosal defense, important disease pathways where SLC transporters provides target for immuno-oncology, inflammatory disorders, and neurological diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Internet Brands

Venture Round in 1999
Since launching in 1998 as CarsDirect.com, Internet Brands has grown to become a fully integrated online media and client services organization focused on four high-value vertical categories: Automotive, Health, Legal and Home / Travel. The company’s award-winning consumer websites lead their categories and serve more than 100 million monthly visitors, while a full range of web presence offerings has established deep, long-term relationships with SMB and enterprise clients. Internet Brands’ powerful, propriety operating platform provides the flexibility and scalability to fuel the company’s continued growth.

Cardlytics, Inc.

Series C in 2010
Cardlytics uses purchase-based intelligence to make marketing more relevant and measurable. They partner with more than 1,500 financial institutions – including Bank of America and PNC – to run their banking rewards programs that promote customer loyalty and deepen banking relationships. In turn, they have a secure view into where and when consumers are spending their money. They use these insights to help marketers identify, reach and influence likely buyers at scale, as well as measure the true sales impact of marketing campaigns. Headquartered in Atlanta, Cardlytics has offices in London, New York, Chicago and San Francisco.

Foresight Mental Health

Series A in 2020
Foresight is a technology-enabled psychiatry and therapy services company. We directly employ psychiatrists, therapists, psychiatric nurse practitioners to treat patients in our offices. Our team of software and biomedical engineers create technology alongside our providers to revolutionize the care we provide.

Fate Therapeutics, Inc.

Series A in 2007
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Tectonic Therapeutic

Seed Round in 2021
Tectonic is a privately held biotechnology company that aims to transform the discovery of novel GPCR-targeted drugs and unlock the therapeutic utility the most challenging receptors in the class. Tectonic’s founders are at the forefront of scientific research in biochemistry and molecular pharmacology with an extensive track record of entrepreneurial achievement.

Satellite Bio

Seed Round in 2020
Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering. It focuses on the development and implementation of proprietary, off-the-shelf, implantable satellite organs as living therapeutic solutions that can transform the lives of millions of patients who suffer from serious diseases.

Dewpoint Therapeutics

Series C in 2022
Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Adimab

Series B in 2008
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

T2 Biosystems

Series B in 2008
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Confluence Technologies

Private Equity Round in 2006
Founded in 1991, Confluence is a global leader in fund administration automation. Confluence helps investment management companies gain unprecedented control by automating every step of the fund administration process including the collection, creation, confirmation, and delivery of investment product data. Results are lower costs, reduced risk, decreased reporting turnaround times, and the scalability to automate more processes without additional resources. Confluence solutions are used by 40 percent of the leading global investment managers, and more than 60 percent of U.S. mutual funds. The Unity platform from Confluence addresses a wide range of problems from performance measurement to customized reporting for a full array of domestic and international managed investment products, including mutual funds, funds of funds, collective funds, separate accounts, and variable products, as well as hedge funds and other alternative investments. Major fund companies such as the Principal Financial Group, T. Rowe Price, and Russell Investments; and service providers such as U.S. Bancorp Fund Services rely on Confluence

TalkIQ

Seed Round in 2016
Since 2014, TalkIQ has offered voice‐to‐text transcription and analytics for clients across a wide variety of industries. Using cutting edge deep‐learning algorithms, proprietary speech recognition and predictive analytics technology, we give our clients visibility into all of their phone conversations, extracting insights for uses ranging from sales optimization, to customer service, compliance, and more. Our recommendations enable teams to save time and maximize productivity, though quick access to action-oriented data & analysis. TalkIQ is backed by prominent Silicon Valley VC firms and is helmed by an advisory board with decades of experience in the speech and language recognition fields.

Folx Health

Seed Round in 2020
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.

FREEjit

Series A in 2010
FREEjit, Inc. is in Stealth mode. The company was incorporated in 2010 and is based in Newport Beach, California.

Space Monkey

Seed Round in 2012
Space Monkey is an affordable subscription-based data storage solution that is taking the cloud out of the datacenter, creating a faster and more durable way to store data from any device. Space Monkey combines the benefits of local hardware storage and cloud storage by providing a device that stores one terabyte of online storage. Space Monkey provides central access and sharing from anywhere in the world, and from any device including iOS and Android mobile devices, Windows, Mac and Linux clients, as well as any other web browser enabled technology. Founded by entrepreneurs, Clint Gordon-Carroll and Alen Peacock in July 2011, Space Monkey is headquartered in Midvale, UT, a suburb of Salt Lake City. For more information, please visit: www.spacemonkey.com

Saegis Pharmaceuticals

Series B in 2003
Saegis Pharmaceuticals is focused on the development of medicines that address behavioral disorders. The company has a pipeline of treatments for central nervous system diseases involving cognitive dysfunction, including Alzheimer’s disease, mild cognitive impairment, attention deficit hyperactivity disorder, and cognitive impairment associated with schizophrenia. It develops CNS therapeutics for patients facing memory loss and cognition deficits associated with aging, psychiatric disorders, and brain trauma. Saegis Pharmaceuticals was founded in 1999 and is based in Half Moon Bay, California.

BIND Therapeutics

Series B in 2007
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Xpressdocs Partners, Ltd.

Venture Round in 2006
Xpressdocs provides on-demand direct marketing solutions for education, financial, healthcare, hospitality, insurance, and real estate industries worldwide. It offers calendars, postcard templates, business cards, brand-building brochures, rack cards, and flyers. The company also provides XpressMail, a template-driven email marketing solution for real estate professionals and small business owners to create personalized emails. In addition, Xpressdocs Partners, Ltd. offers enterprise marketing solutions for multi-user, franchise, and real estate companies ranging from direct mail, digital print, conventional print, custom packaging, bindery, and finishing services, to integrated cross-media marketing campaigns that include print, email, and social media. Further, the company provides a direct enterprise marketing platform for print and mailing services, a template library, list building tools, QR code generator, social media integration, email marketing, and automated programs; and print on-demand for postcards, brochures, flyers, business cards, stationery, letterhead, envelopes, tri-folds, calendars, magnets, rack cards, and more.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

CAMP4 Therapeutics

Series B in 2022
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

Drizly, Inc.

Series B in 2017
Drizly is an e-commerce alcohol marketplace and the best way to shop beer, wine, and spirits. With the speed and convenience of on-demand delivery and shipping, Drizly partners with retailers in 235 markets to offer consumers of legal drinking age unrivaled selection and a transparent, personalized shopping experience. Backed by world-class institutional investors, Drizly partners with retailers to bring their shelves online, helping them to reach new customers, tap into key market and customer insights, and diversify their business to grow sales.

Qualaroo

Venture Round in 2014
Qualaroo is a user research tool for UX designers working in SaaS space. It enables companies to gain valuable insights from their prospects and customers at the moment when they are using the website or app. Qualaroo makes it possible to target prompts by user behavior, specified needs, demographics, or any other internal data. They call these prompts Nudges that can be used to get insights about visitors and influence their behavior.

Cushcraft Corp.

Acquisition in 2003
Cushcraft Corp. designs, develops, manufactures, and distributes antennas and other passive radio frequency (RF) products for broadband wireless, communications, and data connectivity solutions.

Wellthy

Series B in 2021
Wellthy, Inc. provides a concierge service that helps individuals and families to manage and coordinate care for chronically ill, aging, or disabled loved ones using its platform in the United States. It operates a network of family caregivers to help individuals and families find, vet, and coordinate care, as well as provides assistance in the areas of legal, medical, financial, and housing-related issues. The company serves people with aging-related complications, such as dementia and Alzheimer’s, diabetes, heart disease, spinal injuries, and cancer. The company was incorporated in 2014 and is headquartered in New York, New York.

LogMeIn

Series B in 2005
LogMeIn, Inc. (NASDAQ:LOGM) simplifies how people connect with each other and the world around them to drive meaningful interactions, deepen relationships, and create better outcomes for individuals and businesses. Current products include: LogMeIn Pro, LogMeIn Central, LogMeIn Rescue, Bold360, join.me, Jive, LastPass, GoToMeeting, GoToWebinar, GoToTraining, GoToAssist, GoToMyPC, OpenVoice and Grasshopper. Founded in 2003, LogMeIn is headquartered in Boston with additional locations in North America, Europe, Asia and Australia.

Data Sciences International, Inc.

Venture Round in 1997
DSI is a pioneering biomedical research company focused on systems physiology and pharmacology. The recognized global leader in physiologic monitoring, DSI offers telemetry, instrumentation, and software and services that help advance science. DSI serves many industries including: Pharmaceuticals, Academia, Contract Research Organizations, Biological and Chemical Defense, the Medical Device Industry, Government, and Biotechnology companies. They offer solutions that are tailored specifically to meet the unique research needs of their customers. View their video below to learn more about DSI.

Mintera

Series C in 2007
Mintera Corporation develops and markets high speed optical transmission systems. It offers MI 40000XS that provides a transport subsystem for carriers, enterprises, educational institutions, and government agencies. The company also provides fiber-optic transport systems that enable deployment of optical transport in metro-core, regional, long-haul, and ultra long-haul networks. Mintera Corporation was founded in 2000 and is based in Acton, Massachusetts.

Transform Pharmaceuticals

Venture Round in 2002
Transform Pharmaceuticals was a pharmaceuticals company specializing in the discovery of improved formulations and novel crystalline forms of drug molecules. Transform’s product portfolio included Topiramate, an anti-epileptic drug. The company was acquired by Johnson & Johnson in 2005. The company was founded in 1998.

e-Rewards

Private Equity Round in 2008
e-Rewards®, Inc. (ERI) is the global leader in permission-based digital data collection and reporting. From its inception in 1999, e-Rewards, Inc. has become recognized in the market research industry for setting high quality standards through the combination of innovative technology and proven research practices – all toward helping clients discover insights that lead to greater understanding. With over 1,200 employees worldwide and 6 million panelists around the globe, that “world of understanding” is becoming more and more attainable. The company has 25 offices around the world and operates through its business units Research Now, e-Miles, Peanut Labs, Conversition and iPinion, Inc., and is headquartered in Plano, Texas.

Adimab

Series D in 2010
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Fate Therapeutics, Inc.

Series B in 2009
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

TechTarget, Inc.

Series A in 2001
TechTarget provides purchase intent-driven marketing and sales services for enterprise technology companies. The company attracts technology buyers researching companies’ information technology needs, with quality editorial content across more than 140 highly targeted technology-specific websites. TechTarget creates the purchase intent insights that fuel effective marketing and sales activities for clients by understanding tech buyer content consumption. TechTarget helps more than 1,300 tech companies accomplish sustainable pipeline impact. It was founded on 1999 and is headquartered in Newton, Massachusetts.

BridgePoint Medical

Series B in 2007
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.
Remon Medical Technologies is a development-stage company focused on communication technology for medical device applications. It offers RemonCHF, a device that monitors the hemodynamic status of patients with congestive heart failure; and RemonAAA, a device that monitors pressure following an endograft procedure in AAA patients. The company is based in Caesarea, Israel.

FloQast

Series A in 2016
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.

Genocea Biosciences

Series C in 2012
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Useful Networks

Venture Round in 2011
Useful Networks is a mobile application builder that focuses on location-based apps and services. They are a subsidiary of Liberty Media.

e-Rewards

Venture Round in 1999
e-Rewards®, Inc. (ERI) is the global leader in permission-based digital data collection and reporting. From its inception in 1999, e-Rewards, Inc. has become recognized in the market research industry for setting high quality standards through the combination of innovative technology and proven research practices – all toward helping clients discover insights that lead to greater understanding. With over 1,200 employees worldwide and 6 million panelists around the globe, that “world of understanding” is becoming more and more attainable. The company has 25 offices around the world and operates through its business units Research Now, e-Miles, Peanut Labs, Conversition and iPinion, Inc., and is headquartered in Plano, Texas.

BarkBox

Seed Round in 2012
Bark & Co is the handiwork of Matt Meeker, Henrik Werdelin and Carly Strife. Brought together by their love of all things canine, these three launched Bark & Co’s first product, BarkBox, with little thought as to how popular it was going to be. BarkBox is a subscription e-commerce and content company for dog-lovers. As BarkBox grew, so did their understanding of the loyal dog parents that loved their monthly box of goodies. The success of the box led to the creation of Bark & Co, a company that is dedicated to building products that foster the health and happiness of dogs everywhere.

Twistlock Inc.

Series B in 2017
Trusted by 25% of the Fortune 100, Twistlock is the most complete, automated and scalable container cybersecurity platform. From precise, actionable vulnerability management to automatically deployed runtime protection and firewalls, Twistlock protects applications across the development lifecycle and into production. Purpose built for containers, serverless, and other leading technologies - Twistlock gives developers the speed they want, and CISOs the control they need. Founded in 2015 by CEO Ben Bernstein and VP R&D Dima Stopel, Twistlock is privately held with funding from Polaris Partners, 1011 Ventures, Rally Ventures, YL Ventures and Dell Technologies Capital. Twistlock is headquartered in Portland, Oregon with offices in New York City, Baton Rouge, Louisiana, London, and Herzliya, Israel.

Incentive Systems

Series C in 2000
"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Solidworks

Venture Round in 1996
Solidworks offers a portfolio of 3D software tools that enables users to create, stimulate, publish, and manage their data. The company’s products caters to industries such as aerospace, automotive, construction, consumer, engineering, manufacturing, education, government, galleries, energy, and more. Its product portfolio focused on 3D CAD, stimulation, product data management, electrical design, technical communication, and more. Solidworks was founded in 1998 and is based in Waltham, Massachusetts.

Paratek

Series C in 2005
Paratek designs and manufactures adaptive RF front-end component solutions for mobile wireless applications. Paratek's product offerings for multi-mode and multi-band operation cover three major applications : Adaptive Impedance Matching Modules (AIMM), Broadband filters and pre-selectors for RF front-end devices, Radio Antenna Frequency Tuners (RAFTâ„¢). Paratek works collaboratively with customers. That means they listen closely to what your needs and milestones are, and then work to adapt their technology to yours. Applications differ, but the beauty of their adaptive approach is that they can easily fine-tune solutions based around certain operating bands, frequency ranges, and industry protocols. If your need is slightly different from the next, that's where they shine!

Ironwood Pharmaceuticals, Inc.

Venture Round in 2009
Ironwood Pharmaceuticals is an entrepreneurial pharmaceutical company, engages in developing and marketing human medicines. It engages in developing a pipeline of clinical candidates in the areas of gastrointestinal diseases, cardiovascular diseases, pain, and inflammation. The company's operationally independent subsidiary, Microbia Inc., engages in developing and commercializing bioprocesses for use in pharmaceuticals, foods, and specialty and industrial chemicals. Ironwood Pharmaceuticals, Inc. was formerly known as Microbia, Inc. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts.

PacketLight

Series A in 2000
Established in 2000, PacketLight Networks offers a suite of Leading DWDM and CWDM solutions for optical fiber communication, for transport of data, storage, voice and video applications, over dark fiber and WDM networks, featuring high quality, reliability with layer-1 fiber encryption capabilties, ultimate performance and functionality at affordable prices. Their products are distinguished with low power consumption ideal for CLE (Customer Located Equipment) allowing maximum flexibility as well as ease of maintenance and operation and providing true Pay-as-you-grow architecture.

BarkBox

Series A in 2013
Bark & Co is the handiwork of Matt Meeker, Henrik Werdelin and Carly Strife. Brought together by their love of all things canine, these three launched Bark & Co’s first product, BarkBox, with little thought as to how popular it was going to be. BarkBox is a subscription e-commerce and content company for dog-lovers. As BarkBox grew, so did their understanding of the loyal dog parents that loved their monthly box of goodies. The success of the box led to the creation of Bark & Co, a company that is dedicated to building products that foster the health and happiness of dogs everywhere.

Quartet Health, Inc.

Series C in 2018
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.

JibJab Media Inc.

Series B in 2007
JibJab creates content and tools that help people be funny in their digital lives. From its flagship JibJab Ecards, Music Videos, and GIFs, to its new JibJab Camera app, the company has been pioneering new forms of digital fun since its founding by two brothers in a Brooklyn garage in 1999. Now based in Los Angeles, California, the studio is home to world-class artists, technologists and business people working hard in pursuit of their mission to make "billions of people happy."

Egnyte, Inc.

Series C in 2012
In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

Arsia Therapeutics

Seed Round in 2015
Arsia Therapeutics’ mission is to improve access to these life-saving drugs, make them more patient-friendly, and reduce healthcare costs by enabling subcutaneous delivery in non-hospital settings. Biopharmaceuticals are much larger and more fragile than traditional small-molecule drugs. Due to their size, large doses of biologics are often required; and because of their fragility, these drugs must be administered by injection instead of orally. Biologics become unstable and extremely viscous at the high concentrations required for traditional low-volume injections. Consequently, they are frequently administered as high-volume, slow intravenous infusions in a hospital setting. From a patient perspective, receiving treatment via subcutaneous administration can be preferable to intravenous infusion. Subcutaneous administration removes the need for invasive IV ports. Administration at home eliminates time-intensive and expensive hospital visits. Achieving high doses of biologics in a volume suitable for subcutaneous administration presents significant formulation challenges. The major limiting factor is viscosity, which arises when biomolecules are formulated at high concentration. Arsia’s mission is to produce high-concentration biopharmaceutical products with low viscosity, suitable for small-volume subcutaneous injection. Our proprietary platform technology reduces the viscosity of biologics through the addition of inactive ingredients (excipients). Because Arsia’s technology works at the formulation stage, the molecular structure of the drug itself is not affected. Arsia’s technology provides i) a formulation solution for new products in development that have viscosity challenges, ii) a life-cycle management strategy for existing products and iii) a way to differentiate those products from others on the market. For more information on partnering with Arsia, please contact us.

Adimab

Venture Round in 2012
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Notarize

Seed Round in 2016
Notarize operates an online notary public service that enables users to connect with a commissioned online eNotary public by live video call. It offers Notarize, a software service that allows clients to complete the notarization process remotely and entirely online; Notarize for business, a platform for organizations and developers to collect notarized documents; and Notarize for Mortgage, a platform that digitizes the closing process with technology to coordinate lenders, title companies, and borrowers online. Notarize's electronic notary public service is offered to customers via iOS, Android and web Pat Kinsel founded the company as 16 Pins in May 2015. Notarize has its headquarters in Boston in Massachusetts.

Nomad Health

Venture Round in 2022
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.

Living Proof, Inc

Series B in 2011
Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely new molecules and breakthrough technologies for results you can see from across the room.

eRealty.com

Series E in 2003
eRealty.com is an online residential real estate brokerage firm that assists buyers and sellers of homes. The company was founded in 1998 and is based in Houston, Texas.

Bitium

Venture Round in 2016
Bitium is a Santa Monica-headquartered provider of cloud-based identity and access management solutions, including single sign-on, password management, and analytics for small, medium and enterprise businesses. Founded in 2012, the company aims to give growing companies the ability to manage access to all of their web-based applications -- including Google Apps and Office 365, as well as social networks and CRM, collaboration and marketing tools -- in one place without hindering employee adoption of these applications. Organizations such as GroupM, Fullscreen, Movember and Demand Media use Bitium for an easy-to-use solution that delivers increased flexibility and security. Bitium is backed by Polaris Partners, Resolute VC, Double M Partners, Karlin Ventures, Social Leverage and a group of strategic investors in the enterprise cloud space.

Impinj, Inc.

Series D in 2005
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Silicon Optix

Series C in 2004
Silicon Optix is a fabless semiconductor company, supplier of warping integrated circuit (IC) technology – eWARP™. eWARP digital distortion correction allows manufacturers to complement optics with sophisticated electronics imaging in order to achieve superior system designs and add new compelling features to products while reducing cost and complexity of optical systems. Silicon Optix has the only mainstream geometry processing IC in volume production to date. Over seven years of research and development invested in IC design, system design and optics have given Silicon Optix the expertise to be the leader in this emerging technology with large market opportunities.

Momenta Pharmaceuticals

Series C in 2004
Biotechnology company specializing in the characterization and process engineering of complex molecules

Adimab

Series A in 2007
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

SimplyInsured, Inc.

Series A in 2015
SimplyInsured, Inc. owns and operates an online platform that provides health insurance plans and policies for employer groups and small businesses in the United States. It offers medical, dental, and vision plans; and claims services. SimplyInsured, Inc. was founded in 2012 and is based in San Francisco, California.

CapitalStream

Private Equity Round in 2002
CapitalStreamâ„¢ is an integrated software platform enabling commercial banks and finance companies to implement Straight Through Processing (STP) across lending and leasing portfolios. CapitalStream transforms manual paper-based operations into automated enterprises that respond quickly, efficiently and consistently. CapitalStream streamlines sales, origination, credit analysis, decisioning, document generation, closing, funding, booking, account monitoring and ongoing risk management to reduce cost, risk and processing time. For a rapidly growing list of world class financial institutions, CapitalStream has revolutionized business, commercial, equipment and real estate finance operations by integrating and automating disparate functions and systems to double transaction throughput without increasing headcount.

Automotive Titling Company

Acquisition in 2021
Automotive Titling Company, LLC provides vehicle title and registration services for the automotive industry. It serves dealers, fleet managers, and financial companies. Automotive Titling Company, LLC was formerly known as Automotive Titling of Colorado, Inc. and changed its name to Automotive Titling Company, LLC in November 2020. The company was founded in 1972 and is based in Centennial, Colorado.

EXOS

Series B in 2007
EXOS Physical Therapy and Sports Medicine, LLC provides athletic training and physical therapy services. The company was formerly known as D1 Sports Medicine, LLC and changed its name to EXOS Physical Therapy and Sports Medicine, LLC in August 2017. EXOS Physical Therapy and Sports Medicine, LLC was incorporated in 2010 and is based in Franklin, Tennessee. As of August 25, 2017, EXOS Physical Therapy and Sports Medicine, LLC operates as a subsidiary of Exos Partners, LLC.

Keeps

Series B in 2020
2 out of 3 men will start to lose their hair by the age of 35 - but the earlier you take action, the more hair you keep. Keeps is a full-service healthcare company focused exclusively on helping men keep their hair. From expert diagnosis to affordable treatment, patient support to education, Keeps provides a regimen specific to each customer's condition through a seamless digital experience, allowing men to manage hair loss from start to finish. Keeps’ licensed physicians review each customer's information in order to identify and prescribe a unique treatment plan of FDA-approved products, and we sell them at half the price customers would pay at their local pharmacy. With Keeps, customers receive exactly what they need, and nothing they don’t. Keeps is the first brand from Thirty Madison, which is rebuilding the healthcare experience for the modern consumer.

Neuronetics

Series G in 2017
Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Cardurion Pharmaceuticals, LLC

Private Equity Round in 2019
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.

Lob

Series A in 2014
Lob automates direct mail for modern businesses. More than 7,000 companies use Lob’s APIs to move faster and create new growth opportunities. Lob’s APIs dramatically reduce mail processing time, reclaiming thousands of hours and improving data quality. One in four households in the U.S. have received mail generated through Lob’s platform. Headquartered in San Francisco, Lob is backed by leading investors including Y Combinator, First Round Capital and Polaris Partners.

Auron Therapeutics

Series A in 2022
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

PhyFlex Networks

Venture Round in 2004
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Stickybits

Seed Round in 2010
stickybits is the first social object network, connecting the digital and physical worlds. each stickybit is a unique barcode than can be scanned by iPhone or Android devices and then augmented with user generated content. Users can be notified when their codes are scanned, augmented or moved by other people. The company's first product is a beautifully designed pack of stickers that can be purchased on amazon.com. Users can also choose to print out their own codes at home from stickybits.com

Transoma Medical

Series B in 2005
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Wellthy

Series A in 2019
Wellthy, Inc. provides a concierge service that helps individuals and families to manage and coordinate care for chronically ill, aging, or disabled loved ones using its platform in the United States. It operates a network of family caregivers to help individuals and families find, vet, and coordinate care, as well as provides assistance in the areas of legal, medical, financial, and housing-related issues. The company serves people with aging-related complications, such as dementia and Alzheimer’s, diabetes, heart disease, spinal injuries, and cancer. The company was incorporated in 2014 and is headquartered in New York, New York.

Experience, Inc.

Venture Round in 2000
Experience, Inc. started in 1996 to help young adults learn from the experiences of others. More than a bank of resumes or a traditional job board, they help people understand their interests and aptitudes, and how they can apply their talents in the workforce. Their community at its core empowers the next generation workforce to access a world of possibilities.

170 Systems

Series A in 2002
170 Systems is the leading provider of complete software solutions that automate and optimize Financial processes for the world's largest and most ambitious Finance organizations. The company's customers include Bank of Montreal, British Telecom, ConAgra, France Telecom, Juniper Networks, Plains All American, Reader's Digest, Sandia National Laboratories, Select Medical, Thomson Reuters, University of Pennsylvania, and Verizon Wireless. The company's flagship product , the 170 MarkView® Financial Suite, is a complete, proven Financial process automation solution for Accounts Payable (AP), Expense Management, Procurement, Accounts Receivable, General Ledger, Asset Management, Project Re-Billing and Human Resources. Certified with Oracle e-Business Suite and SAP ERP, 170 MarkView provides real-time Oracle and SAP integration, leveraging the ERP's approvals and validations - without risk of data duplication. At the same time, all 170 Systems' offerings employ best practice workflows, advanced capture technologies such as OCR and interfaces appropriate for each type of user: AP processor, line-of-business manager, Finance manager and supplier.

AgBiome, LLC

Venture Round in 2014
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

Cerulean Pharma

Private Equity Round in 2012
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Modelinia

Series A in 2008
Modelinia is the first global media brand dedicated to the best of fashion, beauty, and lifestyle through the eyes and experiences of the world’s supermodels. At Modelinia, supermodels reveal their secrets, ordinary and extraordinary, to help our audience gain the “style confidence” to look and feel their best. Through high-quality videos, news from the industry’s most knowledgeable and coolest sources, up-to-the-minute articles and blogs, live events and contests, and unique technology, Modelinia offers rich, buzz-worthy content. We not only share inside information from supermodels’ front row view of fashion, beauty, healthy living, and travel; we also connect you to the experts who make the models “super” and help you discover your own personal style. Our goal, through the examples of the world’s most beautiful women and style experts, is to inform you (of the best and latest fashion trends), to entertain you (with compelling, multi-platform content), and to inspire you (to be the best you can be). Modelinia: Unleash your inner supermodel.

Kallyope

Series A in 2015
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Imprivata

Series A in 2002
FairWarning’s platform helps healthcare and enterprise organizations comply with regulations, protect sensitive data, and prevent insider threats. A driving force in building the patient privacy monitoring industry, FairWarning expanded to support other highly regulated industries and applications like Salesforce to help customers easily interpret, investigate and detect anomalous user access or behavior. The company combines advanced technologies including machine learning and AI with best practices and managed services to provide the highest level of security to organizations across the globe. Safeguarding over 350 enterprise customers globally, including 35% of U.S. health systems, FairWarning is trusted to protect organizations’ sensitive data while creating a culture of privacy.

Incentive Systems

Series E in 2002
"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Profitero Ltd.

Venture Round in 2018
Profitero Ltd. provides cloud based real-time eCommerce intelligence to retailers and brands, helping them to take advantage of retail channel in order to increase sales globally. It serves brick-and-mortar, FMCG, health and beauty, electronics, online, and other retailers. Profitero Ltd. has a strategic partnership with Kenshoo, Ltd. The company was incorporated in 2010 and is based in Dublin, Ireland.

Hydra Biosciences

Series D in 2009
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Kallyope

Series D in 2022
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Seamless Receipts

Venture Round in 2011
Seamless Receipts enables retailers to interact with customers through email and social media.

1366 Technologies Inc.

Series A in 2010
1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

RetireOne

Venture Round in 2013
RetireOne is the leading, independent platform for fee-based insurance solutions. With offerings from multiple “A” rated companies, RIAs may access this fiduciary marketplace at no additional cost to them or their clients. Tallying over $1 billion of retirement savings and income investments under advisement, RetireOne continues to grow in its mission to provide advisors and their clients valuable retirement solutions that are simple to use, easy to understand, and delivered with outstanding service.

Iora Health

Series E in 2018
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Quartet Health, Inc.

Series D in 2019
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.

InSeal Medical

Seed Round in 2010
InSeal Medical Ltd. develops and manufactures percutaneous vascular closure devices. The company offers InSeal intravascular closure device, which supports the closure of 14-21Fr punctures in vessels of 6-10mm in diameter. Its devices are used for sealing of puncture sites following treatment involving a large bore sheath. The company is based in Caesarea, Israel. InSeal Medical Ltd. operates as a subsidiary of E-Pacing Inc.
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Incentive Systems

Series B in 1998
"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Podimetrics, Inc.

Series C in 2022
Podimetrics, Inc. develops remote temperature monitoring systems for the prevention of diabetic foot ulcers. It offers Podimetrics SmartMat, a wireless in-home monitoring technology that collects foot temperature scans. The company also offers online tools for clinical decision support and population management. Podimetrics, Inc. was founded in 2011 and is based in Somerville, Massachusetts.

480 Biomedical

Series A in 2011
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Art.com

Series C in 2013
We exist so you can have the art you love. This means giving you easy access to incredible art images and top-notch craftsmanship. Because when you find art you love, you'll love your space more... and that's what it's all about. We work with passion to bring you the world's largest art collection. Whatever your interest, your décor style, your inspiration – we're sure to have that piece you can't live without. We believe art is dynamic, personal and connected to now, and the experience of buying and living with it should be too. From the moment you browse our site to the day your art is delivered, our team has one goal in mind: to delight you every step of the way.

Soapstone Networks

Series B in 1998
Soapstone Networks (formerly Avici Systems) developer of Terabit Switch/Router technology aimed at providing the next generation of high performance, IP-based routers to carriers and Internet Service Providers worldwide. Soapstone Networks got liquidated in 2009 July.

1366 Technologies Inc.

Series B in 2010
1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

WellAir Group Limited

Venture Round in 2014
WellAir delivers energy-efficient technologies that enable safe indoor spaces for the health and wellbeing of all individuals. WellAir’s mission is to mitigate microorganisms that lead to infectious diseases, including viruses, by delivering innovative and powerful air cleaning technology and surface disinfection devices.

Quantcast

Series B in 2008
Quantcast processes real-time data at the intersection of commerce and culture, providing useful, actionable insights for brands and publishers. Through Quantcast Measure, we have unlocked the data generated by more than 100 million digital destinations, helping publishers and creators understand and grow their businesses in ways never before possible. With Quantcast Advertise, adaptive modeling and intelligent machines are utilized to help thousands of marketers around the world find and interact with customers anywhere they connect to the digital world. Our more than 600 employees are driven by the potential for big data to radically improve everyone’s connected experiences and transform the way we all make sense of the world.

Frictionless Commerce

Venture Round in 2005
Frictionless Commerce delivers supplier relationship management software to the purchasing organizations. It offers Sourcing software, an enterprise sourcing platform that minimizes the cost of acquisition for various direct and indirect materials, services, and capital equipment. The company serves banking, insurance, professional services, consumer products, discrete manufacturing, life sciences, telecommunications, and utilities markets. Frictionless Commerce, Inc. was founded in 1998 and is based in Newton Square, Pennsylvania with an additional office in London, England. As of June 5, 2006, Frictionless Commerce, Inc. is a subsidiary of SAP AG.

Endius

Series B in 1997
Endius was founded in 1997 to provide less traumatic and more effective surgery for the of patients treated for back pain. The company develops invasive and endoscopic spine surgery products and implants and is committed to developing total spine surgery solutions. The company's products include the Atavi system, the TiTLE, and the MDS microdebrider system. Endius is acquired by Zimmer Biomet Holdings.

Alimera Sciences, Inc.

Series B in 2005
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Ajax Health

Series C in 2019
Ajax Health is a Private equity and venture capital firm specializing in all stages of a company’s lifecycle. It seeks to invest in innovative medical device companies, medtech, healthcare services, digital health, biotechnology and healthcare IT that focus on truly innovative approaches to solving major issues in healthcare. Ajax Health was founded in 2017 and is based in Menlo Park, California with an additional office in New York City, New York.

Adnexus

Series C in 2007
Engages in the development of Adnectins biologics and medicines in the United States

Arsenal Medical

Debt Financing in 2011
Arsenal Medical, Inc., a platform technology company, develops polymer based foams and fibers for the treatment of vascular diseases. It develops in-situ forming foams to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair. The company also provides AxioCore, a core-sheath nanofiber and microfiber technology constructed from known biomaterials, which is used for cell integration and tissue regeneration enabling controlled delivery of a range of biologics and therapeutics. Arsenal Medical, Inc. was founded in 2005 and is based in Watertown, Massachusetts.

CliQr Technologies, Inc.

Series C in 2015
CliQr Technologies, Inc. develops a single platform for modeling, deploying, and managing applications across physical, virtual, and cloud environments. It offers CliQr CloudCenter, an application-defined management platform that provides infrastructure resources and deploys application components and data across datacenter, private, and public cloud environments. The also provides solutions for application migration, IT-as-a-Service, capacity augmentation, DevOps automation, and service providers. It offers its solutions through reseller partners worldwide. The company was founded in 2010 and is based in San Jose, California. As of April 15, 2016, CliQr Technologies, Inc. operates as a subsidiary of Insieme Networks, Inc.

Cityworks

Venture Round in 2016
Since 1996, Cityworks® has been streamlining the way agencies manage public infrastructure and property by combining the power and flexibility of a Geographic Information System (GIS) with the business logic of asset management, permitting and licensing. Recognizing the Geodatabase as an authoritative system of record for land and asset data, Cityworks leverages the ArcGIS® Location Platform [Esri®] to manage workflow, schedule resources and prioritize activities—saving time, optimizing communication and improving operational efficiencies. Time-tested and proven technology, the Cityworks Web GIS-centric platform is Empowering GIS® at more than 600 organizations around the world.

Athenix

Series A in 2001
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Nomad Health

Series D in 2021
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.

Convoq

Series A in 2002
Convoq was founded to develop a more effective solution for collaborating in real time. The company's founder and management team are experienced software entrepreneurs and technologists with proven records for delivering innovative, secure, and scalable products. They have built companies and commercial products and have been successful in deploying applications and infrastructure to some of the world's leading institutions.

Cardurion Pharmaceuticals, LLC

Venture Round in 2021
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.

Jnana

Series A in 2017
Jnana Therapeutics Inc. operates a drug discovery platform focused on solute carrier (SLC). The company is focusing on immunometabolism, lysosomal function, and mucosal defense, important disease pathways where SLC transporters provides target for immuno-oncology, inflammatory disorders, and neurological diseases. The company was founded in 2016 and is based in Boston, Massachusetts.
Tessa Therapeutics is a provider of therapy designed to focus on T cell therapy for solid tumors. The company's therapy specializes in developing virus specific T-cells and CAR T cells for the treatment of lymphoma, enabling healthcare providers to treat cancer patients and improve their lives.

PublicEarth

Series A in 2008
PublicEarth, launched in November 2009, is a free wiki database of and about locations, generated and updated by users. On the site, people create and maintain PlaceBook personal atlases - which organize and manage their personal locations for ease in sharing, searching, travel planning and activity discovery. In May 2009 PublicEarth began developing a stealth "phase 2" which launched in private beta in August 2010. Originally called PlaceBook (or, famously, PlacéBoök), after threats from Facebook, they changed their landmark travel product TripTrace. In February 2010 PublicEarth was sold to an undisclosed recipient, and separated from the TripTrace website. CEO Rubin purchased the TripTrace project and created a new company TripTrace, Inc. to deliver on the vision.

Visterra

Seed Round in 2008
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Remedy Health Media

Seed Round in 1997
Remedy Health Media is an operator of a digital health platform intended to provide health-related information that produces, publishes, and distributes health magazines to consumers and caregivers. It offers content, tools, and real stories related to consumer health and wellness through the development of authentic communities of health information seekers who can interact and learn from a relatable physician, pharmacist, public health, and patient experts that enable the customers to make informed choices about their health and well-being. The company's mission is to empower patients and caregivers with the information and applications needed to efficiently navigate the healthcare landscape and as a result, to permit better health outcomes through the use of its products and services. Remedy Health Media was established in 1994 and is headquartered in New York.

WikiCell Designs

Series A in 2012
WikiCell Designs Inc., a Cambridge, Mass. and Paris, France-based company developing edible forms of food and beverage packaging.

ByHeart

Series B in 2021
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

CubicPV

Venture Round in 2021
CubicPV is a solar industry that relies on legacy technologies with inherent limitations. Conventional solar modules convert sunlight to electricity using a single light-absorbing material and are nearing an efficiency threshold.

Archivas

Series A in 2003
Archivas, Inc. software lets customers store, protect and manage fixed-content data in the most open and operationally efficient online environment available on the market today, in order to meet both internal governance, as well as external compliance regulations. The Archivas Cluster (ArC) simultaneously addresses the need for immediate access to archive data while lowering the total cost of ownership.

Engine Biosciences

Series A in 2021
Engine Biosciences Pte. Ltd. develops a validated platform for drug discovering, developing combination therapeutics, and cellular reprogramming. The company's artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks. It provides test therapies that specifically target genetic interactions, and make analyses and predictions for precision medicine applications. The platform provides drug discovery, such as target discovery, drug repositioning, repurposing, pathway, and massive online analysis (MoA) analysis. It caters to the American fortune 500 companies and research institutions. The company was founded in 2014 and is based in Singapore.

Localytics

Series D in 2015
Upland Localytics is a mobile app analytics and marketing platform. It gives companies the insights and tools they need to improve their mobile app acquisition, engagement, and retention efforts. It provides a family of cloud-based enterprise work management software applications for information technology, process excellence, finance, professional services, and marketing functions within organizations. The company's platform is used in more than 6,000 apps on more than 2 billion devices by companies such as Live Nation, HSN, Comcast, and The New York Times.

mValent

Series B in 2004
[mValent](http://www.mvalent.com/) is a provider of application configuration management solutions. In February of 2009, they were acquired by [Oracle](http://www.crunchbase.com/organization/oracle).

OM1, Inc.

Series D in 2021
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

Sofregen Medical

Series A in 2016
Founded in 2014 to advance technology developed at Tufts University and the University of Pittsburgh, Sofregen is a pioneer in the use of silk, nature’s healing fiber, in a variety of forms to help physicians address soft tissue defects, giving patients a fresh start, restoring confidence, and improving quality of life. Sofregen is committed to restoring function and cosmetic appearance for medical and aesthetic patients worldwide.

Midstream Technologies

Series B in 2001
MidStream Technologies(TM) has developed the world's first dedicated streaming appliance. One box can deliver 16,000 simultaneous broadband streams with unprecedented scalability. A multiple box configuration provides built-in load balancing, failover reliability and the power to deliver millions of concurrent streams. MidStream servers can support every popular streaming format simultaneously & allow for software and appliance upgrades in the field, extending hardware longevity and promoting cost savings.

Jibe

Series B in 2013
At Jibe, we create global recruiting software solutions to help the world’s leading companies identify, engage, and hire the best talent. Jibe's core technology is the Jibe Recruiting Cloud, a SaaS-based platform that enables leading companies to hire the best talent, regardless of their existing systems. Through this platform, Jibe provides a suite of products including personalized career sites and recruiting tools for sourcing, nurturing and marketing to candidates. Jibe currently serves the world's leading Fortune 500 companies, including Johnson & Johnson, FedEx, Marriott, and American Express. Elevated by strategic partnerships with Google and LinkedIn and backed by their expertise in recruiting technology, Jibe continues to be an innovative leader in the changing world of talent acquisition.

Lob

Seed Round in 2013
Lob automates direct mail for modern businesses. More than 7,000 companies use Lob’s APIs to move faster and create new growth opportunities. Lob’s APIs dramatically reduce mail processing time, reclaiming thousands of hours and improving data quality. One in four households in the U.S. have received mail generated through Lob’s platform. Headquartered in San Francisco, Lob is backed by leading investors including Y Combinator, First Round Capital and Polaris Partners.

Lyndra Inc

Series C in 2021
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.

Impinj, Inc.

Series E in 2007
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Ajax Health

Series B in 2018
Ajax Health is a Private equity and venture capital firm specializing in all stages of a company’s lifecycle. It seeks to invest in innovative medical device companies, medtech, healthcare services, digital health, biotechnology and healthcare IT that focus on truly innovative approaches to solving major issues in healthcare. Ajax Health was founded in 2017 and is based in Menlo Park, California with an additional office in New York City, New York.

Akili Interactive Labs

Series D in 2021
Akili builds clinically-validated cognitive therapeutics, assessments, and diagnostics that look and feel like video games. It aims to develop a new type of electronic medicine that can be deployed remotely directly to any patient anywhere, prescribed and tracked by physicians, with the potential to be developed at a fraction of the cost of traditional medical approaches. Akili’s cognitive engine enables three separate clinical game versions for remote data-capture, with features designed for patient engagement. Its proprietary adaptive mechanics allow the software to automatically personalize to the patient’s ability level with no clinician input required. Akili is based in Boston, Massachusetts.

FloQast

Series D in 2021
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.

Infinite Power Solutions

Series C in 2010
Infinite Power Solutions, Inc. (IPS), a U.S. based clean-technology company, is the global leader in developing, marketing and manufacturing solid-state, rechargeable thin-film micro-energy storage devices for a variety of micro-electronic applications. Founded in 2001, IPS is privately held with corporate headquarters and manufacturing facilities in the western suburbs of [Denver, CO](http://www.crunchbase.com/maps/search?range=10&geo=denver,+co). The company has completed the build-out of the world's first volume manufacturing facility dedicated to the production of its revolutionary thin-film micro-energy cell (MEC(TM)) products (often referred to as thin-film batteries). IPS has recently commenced pre-production activities at this state-of-the-art facility to address growing demand among customers in the wireless sensor, active RFID, powered smart card, medical device, consumer electronics, automotive and civil/military/aerospace markets

Athenix

Series B in 2004
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Hummingbird Bioscience

Series C in 2021
Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association, including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas.

ShoeDazzle.com, Inc.

Series C in 2011
ShoeDazzle is a fashion subscription service that brings a personalized boutique experience to an online platform. ShoeDazzle offers VIP Elite Membership for $39.95 each month which converts into rollover “VIP Credits” that members can spend or save for later. Every month, the company debuts a new selection of exclusive and brand-name shoes, handbags and more, including a custom online showroom, curated to each client’s individual style preferences. Rachel Zoe serves as the company’s Chief Stylist.

Vyne

Venture Round in 2009
Vyne, the parent brand of Vyne Medical and NEA Powered by Vyne, is a provider of secure health information exchange and electronic health care communication management solutions. They deliver a single, highly integrated platform for the secure exchange of protected health information and communication management between patients, providers, payers/health plans and partners. Vyne is based in Dunwoody, Georgia, with offices in Knoxville, Tennessee.

Faro Health

Series A in 2021
Clinical protocols are scientific decisions wrapped in administrative burden. The Faro system handles the tedious work better left for a computer, freeing clinical researchers to focus on the important decisions that drive clinical value.

Kojin Therapeutics

Series A in 2021
Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan, and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables the development of selective therapies for a broad range of hard-to-treat diseases. The company’s investors include Polaris Partners, Newpath Partners, Cathay Health, Leaps by Bayer, AbbVie Inc., Eventide Asset Management, Alexandria, and the Dana-Farber Cancer Institute venture firm, Binney Street Capital.

Q1 Labs

Series D in 2007
Qradar, a network security management solution that includes log, threat and compliance management

ClearForest

Series B in 2001
ClearForest is a software company that develops and markets text analytics and text mining solutions. Founded in 1998, ClearForest has its headquarters just outside of Boston and has development in Israel near Tel Aviv.

Sockeye Networks

Series B in 2002
Sockeye Networks is a provider of intelligent routing services. Sockeye Networks enables businesses to intelligently optimize their Internet connectivity, improving network performance, efficiency and visibility. Sockeye Networks developed the industry's first intelligent route optimization service to solve the problems of poor performance, high costs, and limited visibility. The Sockeye Networks GlobalRoute service is the first route optimization solution to integrate local and global Internet traffic conditions to provide real-time network visibility and optimization for multihomed environments. GlobalRoute continuously monitors and analyzes multiple Internet connections in order to select the optimal paths for IP traffic flows. This ensures that customers' network performance and cost goals are realized, enabling them to confidently depend on the Internet for mission-critical applications.
Remon Medical Technologies is a development-stage company focused on communication technology for medical device applications. It offers RemonCHF, a device that monitors the hemodynamic status of patients with congestive heart failure; and RemonAAA, a device that monitors pressure following an endograft procedure in AAA patients. The company is based in Caesarea, Israel.

Kissmetrics

Series B in 2015
Kissmetrics offers behavioral analytics, segmentation, and email campaign automation all in one place. The company connect their experiment results to key business metrics they already track using Kissmetric, streamlines workflow by reviewing experiment results in their familiar Kissmetrics dashboard, and uncover new insights about your experiment using Kissmetrics capabilities Founded in 2008, Kissmetrics is run by a team of designers, developers, and entrepreneurs that are passionate about helping online businesses measure, grow, and monetize.

PartsSource inc.

Venture Round in 2008
PartsSource provides the medical equipment service industry with proprietary software solutions related to the acquisition and life cycle management of medical repair parts. The company has been recognized by clinical engineers and healthcare executives alike for its unique ePartsFinder® application for its ability to increase department efficiencies while reducing costs through its award-winning SmartPrice™ technology.

Sonrai Security Inc.

Series C in 2021
Sonrai Security delivers an enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform is built on a sophisticated graph that identifies and monitors every possible relationship between identities and data that exists inside an organization’s public cloud. Dig’s Governance Automation Engine automates workflow, remediation, and prevention capabilities across cloud and security teams to ensure end-to-end security. The company was founded in 2017 and is headquartered in New York.

Living Proof, Inc

Series A in 2008
Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely new molecules and breakthrough technologies for results you can see from across the room.

Candesant Biomedical

Venture Round in 2019
Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis. It offers a technology that is based on the principle that alkali metals in contact with water generate energy. The insight was that when the amounts of metal and water are controlled, the result is targeted delivery of energy exactly at the site of the water. Its device is designed to target and inactivate the most active sweat glands. The company was founded in 2016 and is headquartered in San Francisco, California.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.
Compass Therapeutics is a clinical-stage biotechnology company targeting the human immune synapse with a new generation of antibody therapeutics. Compass has broadly drugged the immune system by generating epitopically diverse antibody panels to more than 40 targets across all immune cell types and is leveraging its proprietary StitchMabs and common light-chain based multispecific platforms to empirically identify combinations and multispecific with optimized activity. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors. Compass is also progressing several preclinical assets including a novel class of NK cell engagers targeting NKp30 and multiple bispecific checkpoint programs. The company’s offices and labs are based in Kendall Square in Cambridge, Mass.

Cohere Health, Inc.

Series B in 2021
Cohere Health is a patient-journey-focused software-as-a-service company on a mission to significantly improve the experience of patients, providers and health plans; increase the quality of care delivered; lower total cost of care; and increase transparency across the patient care journey.

Asempra Technologies

Series A in 2003
As of May 1, 2009, Asempra Technologies, Inc. was acquired by Bakbone Software Inc. Asempra Technologies, Inc. provides instant recovery solutions for Windows applications and data. It offers Business Continuity Server, a recovery process that enables mid-market IT managers to restore Exchange, SQL, and Windows file servers; and Virtual On-Demand Recovery, a virtualized recovery and data protection solution. The company also provides disaster recovery, data deduplication, data replication, and data protection and recovery services. It has strategic partnerships with Hitachi Data Systems Corporation, Riverbed Technology, Dell EqualLogic, LeftHand Networks, HP, IBM, and Network Appliance. Asempra Technologies, Inc. was founded in 2003 and is headquartered in Santa Clara, California.

eGenesis

Series C in 2021
Egenesis Inc., a biotechnology company, operates as a gene editing and genome engineering that develops human transplantable organs, tissues, and cells. It offers a gene editing platform for developing human compatible organs. The company also provides development, such as gene engineering, single cell cloning, somatic cell nuclear/embryo transfer, organ procurement, and transplantation. The company was incorporated in 2015 and is based in Cambridge, Massachusetts with an additional office in New York, New York.

docTrackr

Seed Round in 2012
Each time you share a digital document, the minute you've sent it, you are no longer in control. docTrackr helps businesses keep their documents under control, wherever they're stored, whomever they're shared with - i.e. you can remotely destroy them, update them and know what people are doing with them in real-time. doctrackr's technology was designed to protect the most sensitive documents in business. docTrackr provides advanced document intelligence and control, giving enterprises complete visibility into document usage. With docTrackr, managers can control permissions, track usage, and even destroy documents remotely. All through all through an easy to use dashboard. They are complementary to document management platforms such as Dropbox, Box.net or Google Drive. docTrackr continues to provide a benefit to their users even once the documents are extracted from their platform and redistributed. docTrackr was part of TechStars – #1 startup accelerator in the world – and is based in the USA (Boston – MA) and in Europe (Paris – France; Bucharest – Romania), and backed by Polaris Ventures and Atlas Ventures. It was acquired by Intralinks.com for $10 million dollars cash.

Lolapps

Series A in 2008
6waves Global Mobile and Social Games Publishing

WellAir Group Limited

Venture Round in 2014
WellAir delivers energy-efficient technologies that enable safe indoor spaces for the health and wellbeing of all individuals. WellAir’s mission is to mitigate microorganisms that lead to infectious diseases, including viruses, by delivering innovative and powerful air cleaning technology and surface disinfection devices.

Visterra

Seed Round in 2009
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Volastra Therapeutics, Inc.

Seed Round in 2020
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.

Noema Pharma

Series A in 2020
Noema Pharma AG operates as a biotechnology company. The company develops therapeutic products and therapies for orphan neurological disorders characterized by imbalanced neuronal networks. It develops and commercializes therapies for conditions affecting the nervous system, including Tuberculosis Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. Noema Pharma AG was founded in 2019 and is based in Basel, Switzerland.

Tausight, Inc.

Series A in 2021
Tausight, Inc. develops a software for reducing healthcare cyber incidents of patient data theft. It serves chief information officer of health care sector. Tausight was founded in 2018 and is based in Sudbury, Massachusetts with additional office in San Francisco, California.

Avitide, Inc.

Series E in 2017
Avitide, Inc. discovers, manufactures, and supplies molecule-specific affinity purification solutions for the biopharmaceutical industry. It offers affinity separation technology that enables customers to achieve bioprocess development timelines, reduce program risk, predict commercial scalability, and reduce manufacturing costs. The company also develops affinity purification solutions for the manufacturing of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. Avitide, Inc. was incorporated in 2012 and is based in Lebanon, New Hampshire.

JibJab Media Inc.

Series C in 2009
JibJab creates content and tools that help people be funny in their digital lives. From its flagship JibJab Ecards, Music Videos, and GIFs, to its new JibJab Camera app, the company has been pioneering new forms of digital fun since its founding by two brothers in a Brooklyn garage in 1999. Now based in Los Angeles, California, the studio is home to world-class artists, technologists and business people working hard in pursuit of their mission to make "billions of people happy."

Amagma, Inc.

Series A in 2020
Amagma Therapeutics is a biotechnology company that specializes in the discovery and development of antibody therapeutics against inflammatory diseases. Its technology overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. The company was founded in 2019 and headquartered in Waltham, Massachusetts.
NextCODE Health is a sequence-based clinical diagnostics company delivering a powerful solution to genome interpretation and big data challenges. Using technology developed over more than 16 years at deCODE genetics, we are enabling the widespread incorporation of genome sequence data into patient diagnosis and care. NextCODE was acquired by WuXi AppTec in 2015 and was renamed WuXi NextCODE before rebranding to [Genuity Science](/organization/genuity-science) in 2020.

AgBiome, LLC

Series C in 2018
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

Pervasis Therapeutics

Series C in 2009
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Visterra

Series C in 2016
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Dyno Therapeutics Inc.

Series A in 2021
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Nanosys

Series C in 2005
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.

XTuit Pharmaceuticals

Series A in 2015
XTuit Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics targeting the disease-promoting microenvironment in fibrotic diseases and cancer. It develops pharmaceutical preparations for use in the diagnosis and treatment of oncological, tumor, and inflammatory diseases. The company was incorporated in 2011 and is based in Waltham, Massachusetts.

Selecta Biosciences

Series B in 2009
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

MedVantx, Inc.

Series C in 2003
Headquartered in San Diego, California, MedVantx is an innovative consumer medication management and delivery company committed to reducing costs and providing information to benefit patients, healthcare providers, payors, employers and manufacturers. Their state-of-the-art mail order pharmacy, operating in Sioux Falls, South Dakota, is licensed in all 50 states and serves as a full line mail order prescription drug and information provider to consumers. Their 35,000 square foot facility recently underwent major upgrades and now meets over 200 cGMP-level quality standards and can properly handle all pharmaceuticals requiring Cold Chain processing. The MedStart Connect program is operational in a number of states including Arizona, California, Florida, Georgia, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Oregon, Pennsylvania, Rhode Island and South Carolina, and serves approximately 4,000 top-decile primary care prescribers. They continue to expand in additional states. MedVantx was recognized by Inc. Magazine in 2009 as the fastest growing privately held healthcare company in the country and 13th fastest overall.

Sirtris Pharmaceuticals

Series A in 2004
[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

DigiCert

Venture Round in 2011
DigiCert, Inc. provides high-assurance SSL certificates to government agencies, financial institutions, educational and medical institutions, and companies worldwide. It offers standard and wildcard SSL certificates, extended validation certificates, and unified communications certificates; and code signing certificate solutions that include Adobe, Apple, Java, and Microsoft code signing certificates. The company also provides managed public key infrastructure solutions that allow organizations to take control of SSL certificate management, including issuing new certificates and reissuing, replacing, and revoking existing SSL certificates. DigiCert, Inc. was founded in 2003 and is based in Lindon, Utah.

Falkonry

Series A in 2018
Falkonry Inc. develops a machine learning software that updates condition recognition capabilities resulting from new data and expert feedback. It offers products, such as Falkonry LRS that multivariates time series data to discover patterns, predict critical events, and explain behaviors in operations; and Falkonry Edge Analyzer, a portable engine enabling predictive models to be deployed on edge devices. The company serves Global Fortune 2000 industrial companies. Falkonry Inc. was founded in 2012 and is based in Sunnyvale, California.

Zingdom Communications

Series B in 2003
Zingdom Communications went out of business. Zingdom Communications, Inc. provides SaaS integrated online meeting and live chat systems for sales, marketing, training, service, and support departments. It offers ASAP family, a flash-based suite with live chat and Web conferencing, including desktop sharing, powerpoint presentations, desktop control, VoIP audio, video, and record and playback.

Bitium

Series A in 2014
Bitium is a Santa Monica-headquartered provider of cloud-based identity and access management solutions, including single sign-on, password management, and analytics for small, medium and enterprise businesses. Founded in 2012, the company aims to give growing companies the ability to manage access to all of their web-based applications -- including Google Apps and Office 365, as well as social networks and CRM, collaboration and marketing tools -- in one place without hindering employee adoption of these applications. Organizations such as GroupM, Fullscreen, Movember and Demand Media use Bitium for an easy-to-use solution that delivers increased flexibility and security. Bitium is backed by Polaris Partners, Resolute VC, Double M Partners, Karlin Ventures, Social Leverage and a group of strategic investors in the enterprise cloud space.

Lyra Therapeutics, Inc.

Series C in 2020
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company’s XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.

Cerulean Pharma

Venture Round in 2006
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

LRN

Series B in 2006
LRN Corporation provides ethics and compliance (E&C) knowledge solutions to companies worldwide. It offers ethics and compliance education solutions that include online courses on universally relevant topics ranging from anti-bribery to trade controls; custom courses; online E&C and compliance materials through mobile devices; and vignettes that capture and present the essence of an ethical principle or compliance challenge. The company also provides E&C advisory services, such as services in the areas of code of conduct; model code system that allows constructing model code of conduct courses; and code of conduct mobile application. In addition, it offers gamification, mobility and adaptive learning, program effectiveness index, and metrics and data solutions; and catalyst AR, an augmented reality application for businesses to enhance compliance programs. LRN Corporation has a strategic partnership with Leeds Equity Partners, LLC. The company was founded in 1992 and is based in Los Angeles, California with additional offices in Los Angeles, New York, Montreal, Paris, London, Santiago, Mumbai, and Australia.

VKernel Corporation

Series A in 2008
VKernel was acquired by Quest Software in 2011. With Dell's acquistion of Quest in September 2012, VKernel is now a part of Dell. Founded in 2007, VKernel Corporation established itself as a leading provider of performance and capacity management products for VMware and Microsoft virtualized infrastructures. VKernel products simplify the complex and critical tasks of planning and predicting capacity utilization and performance bottlenecks. Used by over 50,000 system administrators, the products have proven their ability to maximize capacity utilization, reduce virtualization costs and improve application performance. Led by an experienced and proven management team, VKernel is well-positioned to address the growing demand and opportunity for performance and capacity management solutions for virtualized and cloud environments. The company has operations in the US and in Europe and sells its products directly or through a network of worldwide distribution and reseller partners.

Swiftly

Venture Round in 2017
Swiftly develops enterprise software that helps transit agencies and cities improve urban mobility. Built by transportation experts for transportation professionals, the Swiftly platform harnesses billions of data points and sophisticated algorithms to improve transit system performance, service reliability, and real-time passenger information. Swiftly’s technology platform is installed in over 50 cities from coast to coast, improving transportation services for millions of riders each day. Swiftly was founded on 2014 and is headquartered in San Francisco, California.

Incredible Foods

Venture Round in 2017
Incredible Foods, Inc. manufactures and sells non-dairy frozen products under the brand name perfectlyfree. Its products include fruit bites, frozen bites, and frozen pints. It serves customers through a network of stores. Incredible Foods, Inc. was formerly known as Wikifoods, Inc. and changed its name to Incredible Foods, Inc. in July 2016. The company was founded in 2012 and is based in Boston, Massachusetts. Incredible Foods, Inc. operates as a subsidiary of Quantum Designs, LLC.

Digital Safety Technologies

Venture Round in 2005
Digital Safety Technologies is directly responsible for the manufacture, sales, technical support, and integration of the formerly known Integrian products. The combination of all these attributes allows us to serve and support former Integrian customers, as well as provide advanced solutions to new customers. They have very quickly established DST as a premier supplier of mobile video technology solutions.

Editas Medicine

Series A in 2013
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Gizmoz

Venture Round in 2000
Gizmoz has developed proprietary patented 3D and animation technology to let users express themselves by creating realistic 3D characters made from a single face photo. Gizmoz is the leader in 3D face-mapping technology, face manipulation and automatic face detection with several patents and pending patents in this field. Gizmoz provides a central service to design, manage and transport digital avatars that can be deployed in virtual worlds, online games, PC and console 3D games, social networks, video clips, greeting cards, mobile apps, as well as professional modeling and animation tools.

TARIS BioMedical, Inc.

Series B in 2011
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

MessageGate

Series A in 2003
MessageGate, Inc. provides enterprise email governance software and services. Its products include MessageGate archive categorization, which enables organizations to archive messages by analyzing email traffic as it is sent and received; MessageGate policy enforcement, a policy management solution that can enforce corporate messaging polices and prevent intentional or inadvertent breaches; email filtering, which detects lies in an email, and analyzes header and connection information contained in inbound email traffic and blocks those that are not truthful; and activity profiles, which provide companies with detailed visibility into their current messaging traffic and their email archive contents. The company also offers operational and forensic email analysis; retrospective email archive categorization; and consulting services. Through its consulting services, MessageGate, Inc. provides assistance in the installation and customization of the MessageGate solutions. MessageGate, Inc. was incorporated in 2001 and is based in Bellevue, Washington.

Alimera Sciences, Inc.

Series C in 2008
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Chiaro Networks

Series C in 2000
Chiaro Networks, Inc. engages in the design, manufacture, and delivery of Internet protocol/multi protocol label switching in the United States.

Podimetrics, Inc.

Series B in 2020
Podimetrics, Inc. develops remote temperature monitoring systems for the prevention of diabetic foot ulcers. It offers Podimetrics SmartMat, a wireless in-home monitoring technology that collects foot temperature scans. The company also offers online tools for clinical decision support and population management. Podimetrics, Inc. was founded in 2011 and is based in Somerville, Massachusetts.

First Opinion

Series A in 2014
First Opinion, Inc. designs and develops smart phone based application to connect moms with the doctor who are also mothers through messaging for areas which includes illness, injury, pregnancy, child development, nutrition, lactation, and sleep training. The company was founded in 2013 and is based in San Francisco, California.

Ember Technologies

Venture Round in 2004
Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Volastra Therapeutics, Inc.

Seed Round in 2021
Volastra Therapeutics, Inc., a biotechnology company, develops therapies for the treatment of metastatic cancers. The company offers a library of organoids derived from metastatic cancer samples to elucidate how tumors spread and devise therapeutic strategies that target chromosomal instability during the process of cancer metastasis. Volastra Therapeutics, Inc. was incorporated in 2019 and is based in New York, New York.

Armorblox

Series B in 2021
Armorblox is a venture-backed stealth cybersecurity startup that secures the human layer by using the latest techniques in machine learning (ML) and artificial intelligence (AI) to protect organizations against identity-based attacks and data loss.

BridgePort Networks

Series A in 2004
Fixed-mobile convergence applications for telecommunications service providers

Quartet Health, Inc.

Series B in 2016
Quartet Health, Inc. develops and operates a cloud based platform that allows communication and collaboration between medical providers with behavioral health providers for patient care. Its platform works with health plans and health systems to provide actionable population insights and reports on behavioral health conditions to improve patient outcomes, as well as provides tools for patient self-management. The company was founded in 2014 and is based in New York, New York.

Esurg.com

Series B in 2000
Esurg.com, the most comprehensive and trusted online source for medical, surgical and pharmaceutical supplies and information. They designed Their Web site for the growing number of physician practices and clinics working outside traditional hospital settings — to give them an edge in the increasingly complex business of medicine.

Sosh

Seed Round in 2011
Sosh is a members-only site that helps people discover things to do in their local area with the addition of an integrated social network. Sosh is being built by Offline Labs, a stealthy startup founded by former Google and Slide employees.

Quentis Therapeutics

Series A in 2018
Quentis Therapeutics is a developer of immuno-therapeutics designed to address ER stress in multiple diseases. The company's therapeutics are designed to target ER stress pathways and awaken the immune system's ability to fight cancer, enabling patients to get access to new treatments for cancer.

Cerulean Pharma

Series D in 2011
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

Message Bus

Series A in 2011
Mail Bypass, Inc., doing business as Message Bus, provides a cloud-native application service for enabling and powering messaging across email and mobile channels. Its service enables enterprises and application developers to deliver transactional and marketing messages, including emails, SMS, push mails, and social messages. The company was incorporated in 2010 and is based in Corte Madera, California.

MessageGate

Series B in 2005
MessageGate, Inc. provides enterprise email governance software and services. Its products include MessageGate archive categorization, which enables organizations to archive messages by analyzing email traffic as it is sent and received; MessageGate policy enforcement, a policy management solution that can enforce corporate messaging polices and prevent intentional or inadvertent breaches; email filtering, which detects lies in an email, and analyzes header and connection information contained in inbound email traffic and blocks those that are not truthful; and activity profiles, which provide companies with detailed visibility into their current messaging traffic and their email archive contents. The company also offers operational and forensic email analysis; retrospective email archive categorization; and consulting services. Through its consulting services, MessageGate, Inc. provides assistance in the installation and customization of the MessageGate solutions. MessageGate, Inc. was incorporated in 2001 and is based in Bellevue, Washington.

Alector

Series C in 2015
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Stickybits

Series A in 2010
stickybits is the first social object network, connecting the digital and physical worlds. each stickybit is a unique barcode than can be scanned by iPhone or Android devices and then augmented with user generated content. Users can be notified when their codes are scanned, augmented or moved by other people. The company's first product is a beautifully designed pack of stickers that can be purchased on amazon.com. Users can also choose to print out their own codes at home from stickybits.com
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

eRealty.com

Series B in 2001
eRealty.com is an online residential real estate brokerage firm that assists buyers and sellers of homes. The company was founded in 1998 and is based in Houston, Texas.

Art.com

Venture Round in 2005
We exist so you can have the art you love. This means giving you easy access to incredible art images and top-notch craftsmanship. Because when you find art you love, you'll love your space more... and that's what it's all about. We work with passion to bring you the world's largest art collection. Whatever your interest, your décor style, your inspiration – we're sure to have that piece you can't live without. We believe art is dynamic, personal and connected to now, and the experience of buying and living with it should be too. From the moment you browse our site to the day your art is delivered, our team has one goal in mind: to delight you every step of the way.

Hydra Biosciences

Series A in 2002
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Akamai Technologies

Series B in 1999
Akamai is the provider of cloud services for helping enterprises provide secure, high-performing user experiences on any device, anywhere. If you've ever shopped online, downloaded music, watched a web video or connected to work remotely, you've probably used Akamai's cloud platform. Akamai helps enterprises accelerate innovation in the hyperconnected world by removing the complexities of technology so you can focus on driving your business faster forward. We enable enterprises to capitalize on market opportunities presented by trends like mobile and cloud while overcoming the challenges presented by security threats and the need to reach users globally. The Akamai Intelligent Platform™ reaches globally and delivers locally, providing unmatched reliability, security and visibility into your online business.

Silicon Optix

Series B in 2004
Silicon Optix is a fabless semiconductor company, supplier of warping integrated circuit (IC) technology – eWARP™. eWARP digital distortion correction allows manufacturers to complement optics with sophisticated electronics imaging in order to achieve superior system designs and add new compelling features to products while reducing cost and complexity of optical systems. Silicon Optix has the only mainstream geometry processing IC in volume production to date. Over seven years of research and development invested in IC design, system design and optics have given Silicon Optix the expertise to be the leader in this emerging technology with large market opportunities.

aTyr Pharma, Inc.

Series C in 2010
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Aepona Limited

Series B in 2005
Aepona Ltd. provides application-led products and services to telecommunications operators worldwide. Its Universal Service Platform allows service creation and implementation to be carried out within the service network from underlying network resources. Aepona, Ltd. serves customers in Europe, North America, and South East Asia. The company was founded in 1999 and is headquartered in Belfast, United Kingdom. Aepona Ltd. is a former subsidiary of ApiON Ltd.

Jibe

Seed Round in 2010
At Jibe, we create global recruiting software solutions to help the world’s leading companies identify, engage, and hire the best talent. Jibe's core technology is the Jibe Recruiting Cloud, a SaaS-based platform that enables leading companies to hire the best talent, regardless of their existing systems. Through this platform, Jibe provides a suite of products including personalized career sites and recruiting tools for sourcing, nurturing and marketing to candidates. Jibe currently serves the world's leading Fortune 500 companies, including Johnson & Johnson, FedEx, Marriott, and American Express. Elevated by strategic partnerships with Google and LinkedIn and backed by their expertise in recruiting technology, Jibe continues to be an innovative leader in the changing world of talent acquisition.

TARIS BioMedical, Inc.

Series B in 2017
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Follica, Inc.

Series B in 2010
Follica, Inc. develops a treatment system for hair loss in adult humans. It offers an in-office treatment proprietary device that disrupts the skin and creates new hair follicles; and at-home treatment system that delivers compounds directly to the scalp for a daily routine. Follica, Inc. was incorporated in 2005 and is based in Boston, Massachusetts. Follica, Inc. operates as a subsidiary of PureTech Health plc.

Arivale

Series B in 2015
Arivale Inc. provides wellness services to individuals. It offers individuals with a scientific path to optimize wellness and avoid diseases. The company’s services engages in analyzing various areas of an individual body, such as genome, blood and saliva, gut microbiome, and lifestyle, as well as provides them with actionable recommendations on optimizing their wellness. In addition, it guides individuals on various types of food and exercise that works with their body. Arivale Inc. was incorporated in 2013 and is headquartered in Seattle, Washington.

Incentive Systems

Series A in 1998
"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Jibe

Series A in 2011
At Jibe, we create global recruiting software solutions to help the world’s leading companies identify, engage, and hire the best talent. Jibe's core technology is the Jibe Recruiting Cloud, a SaaS-based platform that enables leading companies to hire the best talent, regardless of their existing systems. Through this platform, Jibe provides a suite of products including personalized career sites and recruiting tools for sourcing, nurturing and marketing to candidates. Jibe currently serves the world's leading Fortune 500 companies, including Johnson & Johnson, FedEx, Marriott, and American Express. Elevated by strategic partnerships with Google and LinkedIn and backed by their expertise in recruiting technology, Jibe continues to be an innovative leader in the changing world of talent acquisition.

B12

Series A in 2016
B12 develops and operates a human-assisted artificial intelligence platform that leverages algorithmic design that streamlines website design process. It offers Orchestra, an online platform that integrates with third party tools, such as e-commerce and blogging platforms, and alerts experts to quality issues in web designs. B12 was formerly known as Unlimited Labs, Inc. The company was founded in 2015 and is based in New York, New York.

goRefer.com

Series A in 2000
goRefer offers a web technology solution that supports the internet consumer intelligence industry.

Kala Pharmaceuticals

Private Equity Round in 2012
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Paratek

Series B in 2004
Paratek designs and manufactures adaptive RF front-end component solutions for mobile wireless applications. Paratek's product offerings for multi-mode and multi-band operation cover three major applications : Adaptive Impedance Matching Modules (AIMM), Broadband filters and pre-selectors for RF front-end devices, Radio Antenna Frequency Tuners (RAFTâ„¢). Paratek works collaboratively with customers. That means they listen closely to what your needs and milestones are, and then work to adapt their technology to yours. Applications differ, but the beauty of their adaptive approach is that they can easily fine-tune solutions based around certain operating bands, frequency ranges, and industry protocols. If your need is slightly different from the next, that's where they shine!

LegalZoom

Series A in 2007
LegalZoom is the nation's most recognized name in law, the alternative to the traditional law firm. The leading provider of online legal document services and legal plans to families and small businesses, LegalZoom offers high quality, affordable legal services, marrying cutting-edge technology with access to experienced attorneys. LegalZoom was founded on the idea that all Americans deserve access to the law; and as of 2011 the company has helped close to two million small businesses and families with their legal needs. Our high quality documents have been accepted in all 50 states, and 94% of customers would refer LegalZoom to their family and friends.

AudioAudit

Series A in 2003
AudioAudit is a business solutions provider to the Advertising and Broadcast industries.

Recurly

Series B in 2014
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.

Simon Data

Series B in 2018
Simon Data, Inc. develops and distributes a performance marketing platform. The company offers core data ingestion, personalization engine, multichannel automation, advanced experimentation support, and cohort-based funnel analysis solutions. Simon Data, Inc. was formerly known as Radico, Inc. and changed its name to Simon Data, Inc. in November 2013. The company was founded in 2013 and is based in Brooklyn, New York.

Vets First Choice

Venture Round in 2012
Vets First Choice provides veterinary practices with an online pharmacy and home delivery services. It partners with veterinarians to create insight into gaps in patient care and offer professionalized pro-active prescription management to drive client engagement and improve compliance. The company was founded by Ben Shaw in 2010 and is based in Portland, Maine.

BridgePort Networks

Series C in 2006
Fixed-mobile convergence applications for telecommunications service providers

Automotive Titling Company

Venture Round in 2020
Automotive Titling Company, LLC provides vehicle title and registration services for the automotive industry. It serves dealers, fleet managers, and financial companies. Automotive Titling Company, LLC was formerly known as Automotive Titling of Colorado, Inc. and changed its name to Automotive Titling Company, LLC in November 2020. The company was founded in 1972 and is based in Centennial, Colorado.

Gauss Surgical, Inc.

Series C in 2018
Gauss Surgical is a med-tech company that develops a vision-based platform for accurate and real-time measurement of surgical blood loss. They develop beautiful applications for iOS backed by sophisticated algorithms and a robust, HIPAA-compliant technical stack to enable real-time monitoring during surgery. The company was incorporated in 2011 and is headquartered in Menlo Park, California.

Iora Health

Series D in 2016
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Sentillion

Series B in 2000
Sentillion, Inc. offers identity and access management technology solutions for caregivers in hospitals and healthcare organizations in North America and the United Kingdom. The company provides solutions for sign-on, user provisioning, clinical workstations, and virtualized remote access. The company offers expreSSO that delivers transparent single sign-on in existing workflows; Bridges, which provides a mechanism for interfacing to applications; and proVision that alters, disables, and terminates access to systems and applications. It also offers Vergence, which unifies single sign-on, single patient selection, and authentication services in clinical workstation solution that enables caregivers to access and navigate between the myriad of clinical and business applications. In addition, it offers vThere, which enables to manage clinicians and staff, such as medical transcriptionists, remote physicians, contractors, and temporarily displaced employees; and IdMPOWER that enables to accelerate the process of incorporating applications and information systems in the company's environment. The company offers implementation services, comprising project planning, installation, training, integrated testing, and deployment; and technical support services, including toll-free telephone support, trouble-shooting, and operational support. Sentillion, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Centive

Venture Round in 2003
Centive focuses exclusively on delivering technology solutions for automating incentive compensation management. Centive's vision from the outset has been to help companies transform sales compensation management from a tactical commission calculation exercise into a strategic management tool for driving sales performance.

Silicon Optix

Series B in 2002
Silicon Optix is a fabless semiconductor company, supplier of warping integrated circuit (IC) technology – eWARP™. eWARP digital distortion correction allows manufacturers to complement optics with sophisticated electronics imaging in order to achieve superior system designs and add new compelling features to products while reducing cost and complexity of optical systems. Silicon Optix has the only mainstream geometry processing IC in volume production to date. Over seven years of research and development invested in IC design, system design and optics have given Silicon Optix the expertise to be the leader in this emerging technology with large market opportunities.

Nanosys

Series B in 2003
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.

Pulmatrix

Series B in 2009
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Phreesia

Series D in 2010
Innovative point-of-service platform drives efficiency and profitability throughout your organization

Veracode, Inc.

Series B in 2007
Veracode is the only independent provider of cloud-based application intelligence and security verification services. The Veracode platform provides the fastest, most comprehensive solution to improve the security of internally developed, purchased, or outsourced software applications and third-party components. It was founded in 2006 and headquartered in Burlington, Massachusetts.

Profitero Ltd.

Series A in 2014
Profitero Ltd. provides cloud based real-time eCommerce intelligence to retailers and brands, helping them to take advantage of retail channel in order to increase sales globally. It serves brick-and-mortar, FMCG, health and beauty, electronics, online, and other retailers. Profitero Ltd. has a strategic partnership with Kenshoo, Ltd. The company was incorporated in 2010 and is based in Dublin, Ireland.

Thing Labs

Series A in 2009
Thing Labs builds web-based software that makes it easy to create, share, explore and enjoy content. Founded by Jason Shellen, a former Googler who worked on Blogger and co-created Google Reader, Thing Labs is the company behind Brizzly and Plinky.

Mesodyne

Pre Seed Round in 2020
Mesodyne's solution is a novel ultra-high energy density, multi-fuel, silent, compact power generator. Our generators convert fuel to electricity with heat and light as intermediaries: a small micro combustor heats a photonic crystal to incandescence and the resulting light is tailored to the bandgap of an infrared cell resulting in unprecedented high efficiencies.
Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Notarize

Series B in 2019
Notarize operates an online notary public service that enables users to connect with a commissioned online eNotary public by live video call. It offers Notarize, a software service that allows clients to complete the notarization process remotely and entirely online; Notarize for business, a platform for organizations and developers to collect notarized documents; and Notarize for Mortgage, a platform that digitizes the closing process with technology to coordinate lenders, title companies, and borrowers online. Notarize's electronic notary public service is offered to customers via iOS, Android and web Pat Kinsel founded the company as 16 Pins in May 2015. Notarize has its headquarters in Boston in Massachusetts.

Prospex Medical

Seed Round in 2005
Prospex Medical, now dormant, was a medical device incubator focused on innovating and incubating novel medical technologies. With an emphasis on regulated medical devices and non-regulated (quasi-consumer) medical products, Prospex Medical explored a wide variety of opportunities in the health care market. Through a process of market identification, clinical and technical research, physician collaboration, intellectual property generation, and proof of concept, Prospex Medical successfully created and spun-out two companies: BridgePoint Medical (www.bridgepointmedical.com) and Apnex Medical (www.apnexmedical.com).

Genuity Science

Series A in 2013
Genuity Science is a contract genomics and data-sourcing, –analytics and –insights organization headquartered in Boston, Massachusetts, USA with offices in Dublin, Ireland and Reykjavik, Iceland. Genuity partners with global biopharma companies to offer deep end-to-end discovery services aimed at catalyzing precision health and improving the quality of life for patients around the world. Services include population-scale, disease-specific data sourcing, high-quality sequencing, robust statistical analysis and software tools for analyzing large datasets and artificial intelligence (AI). The company operates advanced CAP/CLIA genomics laboratories in Woburn, Massachusetts, USA and in Dublin, Ireland and is deeply committed to data stewardship and data governance across its global offices. For more information, see www.genuitysci.com.

Freenome, Inc.

Series A in 2017
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Caledonia Spirits

Series B in 2019
Caledonia Spirits, Inc. produces and distributes gin, vodka, and elderberry cordial beverages. It offers its products through stores in California, Connecticut, Delaware, Georgia, Illinois, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Texas, Vermont, and Washington, D.C.; and Denmark, Hong Kong, Japan, and Quebec. The company was founded in 2008 and is headquartered in Montpelier, Vermont.

Trevena

Series B in 2010
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Suono Bio

Seed Round in 2017
Suono Bio is developing platform technology designed to enable ultra-rapid delivery of therapeutics, including proteins and nucleic acids, to the gastrointestinal (GI) tract. Preclinical studies have demonstrated the capacity to deliver small molecules, proteins, vaccines, and nucleic acids locally and systemically, validating further development of the system.

Imprivata

Series B in 2006
FairWarning’s platform helps healthcare and enterprise organizations comply with regulations, protect sensitive data, and prevent insider threats. A driving force in building the patient privacy monitoring industry, FairWarning expanded to support other highly regulated industries and applications like Salesforce to help customers easily interpret, investigate and detect anomalous user access or behavior. The company combines advanced technologies including machine learning and AI with best practices and managed services to provide the highest level of security to organizations across the globe. Safeguarding over 350 enterprise customers globally, including 35% of U.S. health systems, FairWarning is trusted to protect organizations’ sensitive data while creating a culture of privacy.

Microbia

Series C in 2002
Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Sonrai Security Inc.

Series B in 2020
Sonrai Security delivers an enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform is built on a sophisticated graph that identifies and monitors every possible relationship between identities and data that exists inside an organization’s public cloud. Dig’s Governance Automation Engine automates workflow, remediation, and prevention capabilities across cloud and security teams to ensure end-to-end security. The company was founded in 2017 and is headquartered in New York.

Editas Medicine

Series B in 2015
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Phytel, Inc.

Venture Round in 2010
Phytel, Inc. provides healthcare organizations with population health management software solutions for delivering coordinated care to their patients. It serves accountable care organizations, physician practices, hospitals, health systems, integrated delivery networks, community health centers, and consultants. The company was founded in 1996 and is based in Dallas, Texas. As of May 4, 2015, Phytel, Inc. operates as a subsidiary of International Business Machines Corporation.

Ember Technologies

Series C in 2006
Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Asthmatx

Series C in 2005
Asthmatx, Inc., a medical device company, focuses on developing and commercializing a therapeutic treatment for asthma in the United States. The company has developed a technology that is designed to deliver controlled thermal energy to the airways of adult patients to reduce the mass of airway smooth muscle in a procedure called Bronchial Thermoplasty. Asthmatx offers an interventional medical device, called the Alair System, for the bronchoscopic treatment of patients with moderate to severe asthma. Asthmatx was founded in 2003 and is headquartered in Mountain View, California. As of October 26, 2010, Asthmatx operates as a wholly-owned subsidiary of [Boston Scientific](/organization/boston-scientific).

Africa Healthcare Network

Venture Round in 2016
Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is a life-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability. AHN operates in Rwanda, Tanzania and Kenya.

Dewpoint Therapeutics

Series A in 2019
Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Suneva Medical, Inc.

Debt Financing in 2014
Suneva Medical, Inc. is a privately held medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It provides a novel and differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. The company’s flagship brand, Bellafill is the only dermal filler on the market with five-year safety and efficacy data, and the only dermal filler approved for the correction of facial acne scars. The Suneva Medical product portfolio focuses on compelling, differentiated products that deliver high patient satisfaction and represent a significant business opportunity to its practice partners. The company was founded in 2015 and headquartered in San Diego, California.

Athenix

Series D in 2008
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Turbine

Series B in 2005
Turbine creates and operates online games. It is one of the largest privately-held online gaming studios in North America. Turbine's online games include The Lord of the Rings Online, Shadows of Angmar, Dungeons & Dragons Online, Stormreach and Asheron's Call.

Folx Health

Seed Round in 2020
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.

Allux Medical

Venture Round in 2006
Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Avaki

Series A in 2003
AVAKI provides grid solutions which enable organizations not only to manage but to leverage the explosion in data and applications, within and across enterprises. A grid is a heterogeneous network which appears and functions as one large operating environment. AVAKI grid solutions can be broken down conceptually into two major categories: compute grids and data grids. AVAKI 2.0 delivers the functionality of each, as well as integrated solutions. Any or all aspects of the software can be implemented, depending on an organization's needs.

Egnyte, Inc.

Series D in 2013
In a content critical age, Egnyte fuels business growth by enabling content-rich business processes, while also providing organizations with visibility and control over their content assets. Egnyte’s cloud-native content services platform leverages the industry’s leading content intelligence engine to deliver a simple, secure, and vendor-neutral foundation for managing enterprise content across business applications and storage repositories. More than 16,000 companies trust Egnyte to enhance employee productivity, automate data management, and reduce file-sharing cost and complexity. Investors include Google Ventures, Kleiner Perkins, Caufield & Byers, and Goldman Sachs.

Syros Pharmaceuticals

Series B in 2014
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Navitor Pharmaceuticals

Series B in 2015
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Aspect Medical Systems

Venture Round in 1997
Aspect Medical Systems develop technology that could measure a then unknown element of patient status – the direct effect of drugs and disease on the brain. Today, Aspect is recognized as a pioneer and global market leader in brain monitoring, having led the way to develop proprietary technologies that directly measure these effects and ultimately improve the quality and cost effectiveness of patient care.

Allurent

Venture Round in 2010
Allurent work on online shopping experiences that lead directly to competitive conversion rates and customer satisfaction.
Neogene Therapeutics, Inc. develops T cell therapies to treat cancer. The company was incorporated in 2018 and is headquartered in New York, New York.

Trevena

Series A in 2008
Trevena is a privately held clinical stage biopharmaceutical company based in King of Prussia, PA, dedicated to the discovery and development of GPCR biased ligands. Established in late 2007, Trevena was created to translate groundbreaking research on GPCR signaling into a new generation of medicines. They have three programs in development: TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intraveneous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization. G protein coupled receptors are the targets for more than 30% of all currently marketed therapeutics. There is significant opportunity to improve upon currently marketed GPCR drugs because many have limited efficacy and undesirable adverse effects, which can prevent broader use. Furthermore, many GPCRs are linked to diseases but cannot be translated into medicines because of specific target-related adverse effects. Trevena's biased ligand approach has the potential to address these problems across a wide range of receptors and therapeutic areas.

Pointy

Series B in 2018
Pointy helps stores by bringing products online, allowing them to get found by people who are searching on the web. It was founded in 2014.

Lascaux Co.

Seed Round in 2011
Lascaux Co. is focused on making art fun again on a mass scale.Provider of social networking applications for mobile devices.

Avaki

Venture Round in 2001
AVAKI provides grid solutions which enable organizations not only to manage but to leverage the explosion in data and applications, within and across enterprises. A grid is a heterogeneous network which appears and functions as one large operating environment. AVAKI grid solutions can be broken down conceptually into two major categories: compute grids and data grids. AVAKI 2.0 delivers the functionality of each, as well as integrated solutions. Any or all aspects of the software can be implemented, depending on an organization's needs.

Soapstone Networks

Series A in 1997
Soapstone Networks (formerly Avici Systems) developer of Terabit Switch/Router technology aimed at providing the next generation of high performance, IP-based routers to carriers and Internet Service Providers worldwide. Soapstone Networks got liquidated in 2009 July.

Metacrine

Series A in 2015
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Apnex Medical

Series B in 2009
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Dewpoint Therapeutics

Series B in 2020
Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.

CAMP4 Therapeutics

Series A in 2018
CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Their predictions enables CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

MarkMonitor

Series E in 2008
MarkMonitor, the global leader in enterprise brand protection, offers comprehensive solutions and services that safeguard brands, reputation and revenue from online risks. With end-to-end solutions that address the growing threats of online fraud, brand abuse and unauthorized channels, MarkMonitor enables a secure Internet for businesses and their customers. The company's exclusive access to data combined with its patented real-time prevention, detection and response capabilities provide wide-ranging protection to the ever-changing online risks faced by brands today.

Alimera Sciences, Inc.

Series A in 2004
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Podimetrics, Inc.

Series B in 2019
Podimetrics, Inc. develops remote temperature monitoring systems for the prevention of diabetic foot ulcers. It offers Podimetrics SmartMat, a wireless in-home monitoring technology that collects foot temperature scans. The company also offers online tools for clinical decision support and population management. Podimetrics, Inc. was founded in 2011 and is based in Somerville, Massachusetts.

ARPU

Series B in 2006
ARPUinc is a privately held Washington DC-based technology company, focused on enabling a superior advertising and ecommerce experience for consumers, advertisers, and publishers alike. By enhancing the ease of registration and purchase for the consumer, ARPU increases the efficacy of the online channel across all three constituencies. For online advertisers and publishers, ARPU augments the effectiveness of online advertising, thereby significantly driving ROI. With a distribution network that reaches more than 20 million unique visitors per month, ARPU's roster of advertiser and publisher partners spans from PC security and utility software providers to education and entertainment services to PC OEMs and ISPs.

FloQast

Series B in 2017
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Linguateq

Venture Round in 2000
Linguateq offers datastream management system and patented data integration software that reduces complexity, time-to-market, and cost. It specializes in legacy and emerging platforms, switches, networks, and industry standards such as BAF/AMA, ASN.1, AMADNS, and IPDR. The company enables its customers to achieve interoperability in any architecture and maximizes their revenue and profit in today's competitive marketplace. Linguateq was founded in 1995 and is headquartered in Mclean, Virginia.

Cardiac Dimensions

Series D in 2007
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Vico Therapeutics B.V.

Series A in 2020
Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

Freenome, Inc.

Series B in 2019
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

BridgePoint Medical

Series A in 2006
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Drizly, Inc.

Series C in 2018
Drizly is an e-commerce alcohol marketplace and the best way to shop beer, wine, and spirits. With the speed and convenience of on-demand delivery and shipping, Drizly partners with retailers in 235 markets to offer consumers of legal drinking age unrivaled selection and a transparent, personalized shopping experience. Backed by world-class institutional investors, Drizly partners with retailers to bring their shelves online, helping them to reach new customers, tap into key market and customer insights, and diversify their business to grow sales.

Ajax Health

Series C in 2019
Ajax Health is a Private equity and venture capital firm specializing in all stages of a company’s lifecycle. It seeks to invest in innovative medical device companies, medtech, healthcare services, digital health, biotechnology and healthcare IT that focus on truly innovative approaches to solving major issues in healthcare. Ajax Health was founded in 2017 and is based in Menlo Park, California with an additional office in New York City, New York.

Avila Therapeutics

Series A in 2007
Avila Therapeutics, Inc. designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics, Inc. has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts. As of March 7, 2012, Avila Therapeutics, Inc. operates as a subsidiary of Celgene Corporation.

Twistlock Inc.

Series C in 2018
Trusted by 25% of the Fortune 100, Twistlock is the most complete, automated and scalable container cybersecurity platform. From precise, actionable vulnerability management to automatically deployed runtime protection and firewalls, Twistlock protects applications across the development lifecycle and into production. Purpose built for containers, serverless, and other leading technologies - Twistlock gives developers the speed they want, and CISOs the control they need. Founded in 2015 by CEO Ben Bernstein and VP R&D Dima Stopel, Twistlock is privately held with funding from Polaris Partners, 1011 Ventures, Rally Ventures, YL Ventures and Dell Technologies Capital. Twistlock is headquartered in Portland, Oregon with offices in New York City, Baton Rouge, Louisiana, London, and Herzliya, Israel.

1366 Technologies Inc.

Series C in 2013
1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

Sun Catalytix

Seed Round in 2009
Located in Cambridge, MA, Sun Catalytix is an early-stage renewable energy startup founded on groundbreaking science from the research lab of Professor Daniel Nocera at MIT. With Nature as our inspiration, we seek to combine sunlight and water to provide affordable, highly distributed solar energy to the individual. The elemental components of just 3 gallons of water have enough energy, when recombined, to satisfy the daily energy needs of a large American home. The US receives 500-fold more energy each year than it uses, but unfortunately the sun shines only half the time. At Sun Catalytix we are working to realize the dream of cheap, renewable, personalized energy allowing individuals to use the power around-the-clock. Backed by Polaris Venture Partners, we have started down the path to a sustainable energy future.

Momenta Pharmaceuticals

Series B in 2003
Biotechnology company specializing in the characterization and process engineering of complex molecules

Infinite Power Solutions

Series D in 2012
Infinite Power Solutions, Inc. (IPS), a U.S. based clean-technology company, is the global leader in developing, marketing and manufacturing solid-state, rechargeable thin-film micro-energy storage devices for a variety of micro-electronic applications. Founded in 2001, IPS is privately held with corporate headquarters and manufacturing facilities in the western suburbs of [Denver, CO](http://www.crunchbase.com/maps/search?range=10&geo=denver,+co). The company has completed the build-out of the world's first volume manufacturing facility dedicated to the production of its revolutionary thin-film micro-energy cell (MEC(TM)) products (often referred to as thin-film batteries). IPS has recently commenced pre-production activities at this state-of-the-art facility to address growing demand among customers in the wireless sensor, active RFID, powered smart card, medical device, consumer electronics, automotive and civil/military/aerospace markets

ClearSky Data, Inc.

Series B in 2015
ClearSky Data’s global storage network simplifies the entire data lifecycle and delivers enterprise storage as a fully managed service. Its storage is designed for business agility. ClearSky simplifies enterprise storage by providing an SLA-based managed service across the global network. The company's patent-pending Smart Tiered Caching continually categorizes data and places it in the right cache layer (hot, warm, cold) based on evolving usage requirements and customer policies. Customers simply scale as needed, using the ClearSky dashboard to add unlimited capacity with a few clicks. All data can be moved across the ClearSky network to meet a variety of use cases including data center migration, load balancing, expansion into new regions, or disaster recovery. ClearSky has partnered with major public clouds to place hot and warm cache copies at the cloud edge. The result: customers get low-latency access to cloud instances, providing a new cost-effective option to run their most demanding workloads. The total cost of ownership (TCO) of storing data using the ClearSky service is about 1/3 the cost of managing it in a company’s data center on physical storage arrays. By leveraging the architecture and building redundancy into all cache layers and network paths, ClearSky is able to provide an enterprise-class service with guaranteed high availability. Industry-leading security technologies and best practices ensure that customer data is always protected and isolated from the moment it enters the ClearSky network. Customers simply plug into the ClearSky service to get the storage they need, when and where they need it, with the security, scalability, and resilience that a business depends on.

SnappCloud

Series C in 2007
SnappCloud brings apps to the world's premier devices. The demand for apps on devices is staggering. According to Gartner, in 2011, over 800 million PCs, tablets and smartphones were sold. In 2016, over 2.5 billion of these devices will be sold. 64% of consumers say that on their next device upgrade they want apps built for the device. SnappCloud helps device makers and app developers meet the demand. They design, build, and operate branded app stores for device makers. Their curated approach brings best-in-class apps to customers. SnappCloud is located in Washington, DC. For more information, please visit http://snappcloud.com/ or follow @SnappCloud.

Allaire Corporation

Seed Round in 1997
Allaire Corporation operates an Internet business platform which creates e-commerce, content management, customer service, and business automation systems.

Centive

Venture Round in 2005
Centive focuses exclusively on delivering technology solutions for automating incentive compensation management. Centive's vision from the outset has been to help companies transform sales compensation management from a tactical commission calculation exercise into a strategic management tool for driving sales performance.

Allurent

Series B in 2007
Allurent work on online shopping experiences that lead directly to competitive conversion rates and customer satisfaction.

TARIS BioMedical, Inc.

Series A in 2009
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Visterra

Series B in 2014
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Strata Health Solutions

Venture Round in 2014
Strata Health leverages technology to achieve dramatic patient flow improvement within health systems. Our clients say they’ve entrusted us with the job of creating patient flow solutions that achieve real and dramatic benefits for patients, their families and the world’s devoted front line caregivers. Operational in Canada and the UK, Strata Health is a privately held Canadian corporation. It is comprised of professionals with empathy for those who need care and intense respect for those who devote themselves to caring for others.

eRealty.com

Series D in 2002
eRealty.com is an online residential real estate brokerage firm that assists buyers and sellers of homes. The company was founded in 1998 and is based in Houston, Texas.

T2 Biosystems

Series A in 2006
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Mintera

Series B in 2006
Mintera Corporation develops and markets high speed optical transmission systems. It offers MI 40000XS that provides a transport subsystem for carriers, enterprises, educational institutions, and government agencies. The company also provides fiber-optic transport systems that enable deployment of optical transport in metro-core, regional, long-haul, and ultra long-haul networks. Mintera Corporation was founded in 2000 and is based in Acton, Massachusetts.

Neuronetics

Series F in 2015
Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Alector

Series D in 2016
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Matrics

Series B in 2002
Matrics is a provider of RFID technology and visibility solutions for supply chain, asset management and security. Patented wireless tracking technologies provide users with the most reliable and cost-effective solutions to provide the comprehensive visibility of assets throughout an enterprise.

Kala Pharmaceuticals

Series B in 2014
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

BridgePoint Medical

Series C in 2011
BridgePoint Medical, a private company with headquarters in Minneapolis, Minnesota, is focused on developing innovative and proprietary technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.

Visterra

Series A in 2012
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Wakonda Technologies

Series A in 2008
Wakonda Technologies was founded in 2005 by Dr. Les Fritzemeier and Professor Ryne Raffaelle of the Rochester Institute of Technology. The company was established to exploit the intersection of their respective skills in metallurgical processing and advanced photovoltaic devices. Wakonda was started in Rochester NY and used the facilities at RIT, Cornell University and several government agencies to conduct proof of concept experiments. In 2008, the company moved to Massachusetts to accelerate product development and early commercialization. Wakonda has received several honors over its short history, winning the first ever Golden Horseshoe Business Challenge in upstate NY and being named the National Renewable Energy Laboratory's Entrepreneur of the Year in 2007.

CapitalStream

Venture Round in 2000
CapitalStreamâ„¢ is an integrated software platform enabling commercial banks and finance companies to implement Straight Through Processing (STP) across lending and leasing portfolios. CapitalStream transforms manual paper-based operations into automated enterprises that respond quickly, efficiently and consistently. CapitalStream streamlines sales, origination, credit analysis, decisioning, document generation, closing, funding, booking, account monitoring and ongoing risk management to reduce cost, risk and processing time. For a rapidly growing list of world class financial institutions, CapitalStream has revolutionized business, commercial, equipment and real estate finance operations by integrating and automating disparate functions and systems to double transaction throughput without increasing headcount.

AgBiome, LLC

Series B in 2015
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

ShoeDazzle.com, Inc.

Series A in 2009
ShoeDazzle is a fashion subscription service that brings a personalized boutique experience to an online platform. ShoeDazzle offers VIP Elite Membership for $39.95 each month which converts into rollover “VIP Credits” that members can spend or save for later. Every month, the company debuts a new selection of exclusive and brand-name shoes, handbags and more, including a custom online showroom, curated to each client’s individual style preferences. Rachel Zoe serves as the company’s Chief Stylist.

InsideSales.com, Inc.

Series D in 2015
XANT delivers the industry-leading sales engagement AI platform powered by Real DataTM. XANT provides solutions that accelerate revenue by enabling (sales) teams to build a better pipeline and close more deals. Our core differentiation stems from RealData that like modern AI apps such as WAZE, Netflix and Amazon use data though a collective that drives insights, scores and predictions across email, voice, LinkedIn, SMS interactions. Hundreds of customers across the globe including companies such as American Express, Cisco, John Hancock, and Pluralsight, trust XANT to drive productivity, visibility, and effectiveness in their prospect and customer interactions.

B2Gnow

Venture Round in 2021
B2Gnow develops a turn-key, hosted software solution that streamlines and automates data-gathering, tracking, reporting, vendor management, and administrative processes. The result is a significant reduction in staff time and cost, allowing customers to focus on meeting their diversity goals. B2Gnow can save organizations 60%-80% of time spent on administrative and clerical activities while enhancing the impact and reach.

Archivas

Series C in 2006
Archivas, Inc. software lets customers store, protect and manage fixed-content data in the most open and operationally efficient online environment available on the market today, in order to meet both internal governance, as well as external compliance regulations. The Archivas Cluster (ArC) simultaneously addresses the need for immediate access to archive data while lowering the total cost of ownership.

Alector

Series A in 2013
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in phase II clinical trial for the treatment of frontotemporal dementia disease; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer’s and Parkinson’s diseases. The company also offers AL002 and AL003, which are in phase 1b clinical trial for the treatment of Alzheimer’s disease. In addition, it has 10 programs under research and development stage. The company has a collaboration agreement with Adimab, LLC for the research and development of antibodies. Alector, Inc. was founded in 2013 and is headquartered in South San Francisco, California.

Research Now Group, Inc.

Venture Round in 2002
At Research Now, they have built their reputation on building relationships. Long lasting, mutually beneficial relationships. It is a philosophy that drives every facet of their company and paves the way for a bright and successful future. As a part of the e-Rewards, Inc. family of companies, they are the world’s leading B2B and B2C panel provider and data collection services company, and uniquely positioned as a true single source solutions provider for any and all research projects.

Allstacks

Seed Round in 2019
Allstacks is a predictive, curated Business Intelligence for Software Engineering Managers. It is the leading predictive forecasting and risk management solution for software development. We deliver business outcomes, not just metrics. It was founded by Hersh Tapadia and Jeremy Freeman in 2017 and is based in Raleigh, North Carolina.

Imprivata

Series A in 2005
FairWarning’s platform helps healthcare and enterprise organizations comply with regulations, protect sensitive data, and prevent insider threats. A driving force in building the patient privacy monitoring industry, FairWarning expanded to support other highly regulated industries and applications like Salesforce to help customers easily interpret, investigate and detect anomalous user access or behavior. The company combines advanced technologies including machine learning and AI with best practices and managed services to provide the highest level of security to organizations across the globe. Safeguarding over 350 enterprise customers globally, including 35% of U.S. health systems, FairWarning is trusted to protect organizations’ sensitive data while creating a culture of privacy.

Spindle, Inc.

Venture Round in 2012
Spindle, Inc. provides payment-processing services to merchants using its Catalyst Gateway. It also acts as an agent, independent contractor, or referral partner to broker merchants that it secures to other merchant processors for ongoing fees based on processing volume. The company serves small and medium-sized businesses. The company is based in Marco Island, Florida.

EXOS

Venture Round in 2012
EXOS Physical Therapy and Sports Medicine, LLC provides athletic training and physical therapy services. The company was formerly known as D1 Sports Medicine, LLC and changed its name to EXOS Physical Therapy and Sports Medicine, LLC in August 2017. EXOS Physical Therapy and Sports Medicine, LLC was incorporated in 2010 and is based in Franklin, Tennessee. As of August 25, 2017, EXOS Physical Therapy and Sports Medicine, LLC operates as a subsidiary of Exos Partners, LLC.

CodeRyte

Series D in 2008
CodeRyte is the premier provider of computer-assisted coding and clinical data extraction solutions for the healthcare industry. Their sophisticated technology streamlines the coding process and identifies clinically relevant information from medical records. Their clients secure their rightful reimbursement, enhance compliance and efficiency through computer-assisted coding. CodeRyte's data extraction solutions analyze the language of physician narratives and elevate previously undiscovered data for critical treatment and business decisions. Many of the nation's top physician practices, billing companies and academic medical centers rely on CodeRyte as the centerpiece of their coding and data mining operations.

TARIS BioMedical, Inc.

Venture Round in 2015
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Apnex Medical

Series C in 2012
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

Integrian

Series B in 2005
Integrian develops and manufactures mobile digital video solutions for the public safety.

Sun Catalytix

Series B in 2010
Located in Cambridge, MA, Sun Catalytix is an early-stage renewable energy startup founded on groundbreaking science from the research lab of Professor Daniel Nocera at MIT. With Nature as our inspiration, we seek to combine sunlight and water to provide affordable, highly distributed solar energy to the individual. The elemental components of just 3 gallons of water have enough energy, when recombined, to satisfy the daily energy needs of a large American home. The US receives 500-fold more energy each year than it uses, but unfortunately the sun shines only half the time. At Sun Catalytix we are working to realize the dream of cheap, renewable, personalized energy allowing individuals to use the power around-the-clock. Backed by Polaris Venture Partners, we have started down the path to a sustainable energy future.
Remon Medical Technologies is a development-stage company focused on communication technology for medical device applications. It offers RemonCHF, a device that monitors the hemodynamic status of patients with congestive heart failure; and RemonAAA, a device that monitors pressure following an endograft procedure in AAA patients. The company is based in Caesarea, Israel.

Zingdom Communications

Series A in 2002
Zingdom Communications went out of business. Zingdom Communications, Inc. provides SaaS integrated online meeting and live chat systems for sales, marketing, training, service, and support departments. It offers ASAP family, a flash-based suite with live chat and Web conferencing, including desktop sharing, powerpoint presentations, desktop control, VoIP audio, video, and record and playback.

Vhoto

Seed Round in 2014
Founded by tech-startup veterans and based in the heart of Seattle, Vhoto is an iOS app that leverages the richness of HD video to capture and share life’s best highlights - which we call vhotos. Using machine learning and computer vision technology, Vhoto quickly and intelligently finds the best GIFs and photos from video all in the palm of your hand.

Alimera Sciences, Inc.

Series C in 2009
Alimera Sciences is a pharmaceutical company that specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. They are presently focused on diseases affecting the back of the eye, or retina because these diseases are not well treated with current therapies and will affect millions of people in their aging populations. It was founded in 2003 and is headquartered in Alpharetta, Georgia.

Soapstone Networks

Series C in 1999
Soapstone Networks (formerly Avici Systems) developer of Terabit Switch/Router technology aimed at providing the next generation of high performance, IP-based routers to carriers and Internet Service Providers worldwide. Soapstone Networks got liquidated in 2009 July.

Kronos Bio, Inc.

Series A in 2019
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

The Center from Health Promotion

Venture Round in 2003
The Center for Health Promotion Inc. delivers tobacco cessation and weight management services to customers nationwide. As an operating unit of Group Health Cooperative (Seattle) for almost 20 years, CHP developed the telephone-based Free & Clear program and established itself a national leader in tobacco cessation. Today CHP continues to deliver tobacco cessation services through health plans, businesses and labor organizations around the country. CHP also provides phone-based tobacco cessation services to residents of Georgia, Maine, Minnesota, Oklahoma, Oregon, Utah, Washington and Wisconsin through contracts with state agencies or coalitions. The company is actively engaged in research trials with major research centers including The Stanford Research Institute in Menlo Park, Calif., the Center for Health Research in Portland, Ore., and the Fred Hutchison Cancer Research Center and Group Health's Center for Health Studies, both in Seattle. This active research is undertaken to help improve CHP's services to smokers and increase scientific understanding of this key health issue.

Aria Retirement Solutions

Venture Round in 2012
RetireOne is the leading, independent platform for fee-based insurance solutions. With offerings from multiple “A” rated companies, RIAs may access this fiduciary marketplace at no additional cost to them or their clients. Tallying over $1 billion of retirement savings and income investments under advisement, RetireOne continues to grow in its mission to provide advisors and their clients valuable retirement solutions that are simple to use, easy to understand, and delivered with outstanding service.

Transoma Medical

Series C in 2007
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

Transoma Medical

Series A in 2002
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

1366 Technologies Inc.

Series E in 2019
1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

ARPU

Series C in 2008
ARPUinc is a privately held Washington DC-based technology company, focused on enabling a superior advertising and ecommerce experience for consumers, advertisers, and publishers alike. By enhancing the ease of registration and purchase for the consumer, ARPU increases the efficacy of the online channel across all three constituencies. For online advertisers and publishers, ARPU augments the effectiveness of online advertising, thereby significantly driving ROI. With a distribution network that reaches more than 20 million unique visitors per month, ARPU's roster of advertiser and publisher partners spans from PC security and utility software providers to education and entertainment services to PC OEMs and ISPs.

Phreesia

Series D in 2010
Innovative point-of-service platform drives efficiency and profitability throughout your organization

Kallyope

Series B in 2018
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Adagio Therapeutics, Inc.

Series A in 2020
Adagio Therapeutics, Inc., a biotechnology company, develops antibodies that neutralize SARS-CoV-2, SARS-CoV-1, and potentially emergent coronaviruses. Its portfolio includes multiple, non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company was incorporated in 2020 and is based in Waltham, Massachusetts.

Alnylam Pharmaceuticals

Venture Round in 2003
Alnylam (Nasdaq: ALNY) is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

Living Proof, Inc

Series C in 2013
Living Proof was created for the purpose of applying advanced technology to solve the toughest beauty challenges from a completely fresh perspective. They are a team of scientists from outside beauty, led by MIT Institute Professor Dr. Bob Langer, and beauty authorities with a shared vision: to invent efficient formulas based on entirely new molecules and breakthrough technologies for results you can see from across the room.

Visterra

Series A in 2013
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Arsenal Medical

Venture Round in 2010
Arsenal Medical, Inc., a platform technology company, develops polymer based foams and fibers for the treatment of vascular diseases. It develops in-situ forming foams to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair. The company also provides AxioCore, a core-sheath nanofiber and microfiber technology constructed from known biomaterials, which is used for cell integration and tissue regeneration enabling controlled delivery of a range of biologics and therapeutics. Arsenal Medical, Inc. was founded in 2005 and is based in Watertown, Massachusetts.

Microchips Biotech, Inc.

Venture Round in 2010
Microchips Biotech, Inc. is dedicated to improving the lives of patients by revolutionizing drug delivery. Our proprietary microchip-based implant can store and release precise doses of drugs over months and years. The implant, which is placed under the skin by a trained physician during a simple office procedure using local anesthesia, can be wirelessly activated or deactivated by a physician or patient, without requiring removal. In addition, physicians can wirelessly modify the frequency or dose of the drug to meet the individual needs of each patient.

ReadyForZero

Series A in 2011
ReadyForZero creates online financial software that helps people tackle any debt and protect their credit - automatically. It's not a "debt negotiation" or "debt settlement" service. The company was co-founded by Rod Ebrahimi and Ignacio Thayer as part of Y Combinator in the Summer of 2010. ReadyForZero is a venture-backed technical product team based in San Francisco.

Genocea Biosciences

Series A in 2009
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

eRealty.com

Venture Round in 2000
eRealty.com is an online residential real estate brokerage firm that assists buyers and sellers of homes. The company was founded in 1998 and is based in Houston, Texas.

Nanosys

Seed Round in 2001
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.

Visterra

Debt Financing in 2010
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Veracode, Inc.

Series C in 2009
Veracode is the only independent provider of cloud-based application intelligence and security verification services. The Veracode platform provides the fastest, most comprehensive solution to improve the security of internally developed, purchased, or outsourced software applications and third-party components. It was founded in 2006 and headquartered in Burlington, Massachusetts.

Zingdom Communications

Series C in 2006
Zingdom Communications went out of business. Zingdom Communications, Inc. provides SaaS integrated online meeting and live chat systems for sales, marketing, training, service, and support departments. It offers ASAP family, a flash-based suite with live chat and Web conferencing, including desktop sharing, powerpoint presentations, desktop control, VoIP audio, video, and record and playback.

The Roberts Group

Venture Round in 2014
TRG Screen was founded in 1998 in order to fill this void within the Financial Services industry. TRG's management has been responsible for the administration of over $100,000,000 in market data expenses for major financial institutions. We have been critical in the development of systems and processes designed to analyze market data expenditures, confirm billing accuracy, and allocate the costs all the way down to the individual user level. As a result, those organizations were able to achieve complete cost transparency of all market data expenses.

Focus Financial Partners

Venture Round in 2009
Focus Financial Partners is a partnership of independent, fiduciary wealth management firms. Focus provides access to best practices, resources, and continuity planning for its partner firms who serve individuals, families, employers and institutions with comprehensive wealth management services. Focus partner firms maintain their operational independence, while they benefit from the synergies, scale, economics and best practices offered by Focus to achieve their business objectives.

AgBiome, LLC

Series A in 2013
AgBiome, LLC, a biotechnology company, engages in delivering research and discovery to the agriculture industry. The company develops biological product that controls the predominant soil-borne diseases of greenhouse and major row crops. It identifies plant-associated microbes that enhance plant health, pest resistance, and yield applying based on genomics and screening technologies. AgBiome, LLC has strategic partnerships with Genective and ElevateBio. The company was incorporated in 2012 and is based in Durham, North Carolina.

Genocea Biosciences

Series B in 2011
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

Novaerus

Venture Round in 2014
Novaerus's mission is to improve the business and quality of care through the application of airborne pathogen control technology. Novaerus believe that the preventative approach is the proper path to improved business and quality results in skilled nursing and assisted living facilities. Traditionally, important steps have been taken to clean hands and surfaces. Protocols exist on hand washing, surface cleaning and disinfectant and even isolation used as a tactic to prevent pathogens. When used in conjunction with these traditional methods, the Novaerus technology can go beyond just scrubbing hands and surfaces.

Fate Therapeutics, Inc.

Series B in 2011
Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation's research hotbeds (Boston, San Francisco, San Diego, and Seattle) who have demonstrated the potential to create and modulate stem cells to restore health. The backstory is that while others were working towards therapies based on transplanting stem cell-derived cells into patients, Randall Moon (HHMI and the University of Washington) and Alex Rives (Arch Venture Capitol) envisioned a different approach to develop regenerative therapies. The concept, based on data from hematopoietic progenitor cells, was that one could modulate the properties of stem cells in vivo using small molecules or biologics. They presented this idea to Arch Venture Capitol in Seattle, which launched the company, soon to be joined by other investors.

Receptos

Series B in 2013
Receptos is a privately-held drug discovery and development company which utilizes pioneering G protein-coupled receptor (GPCR) technology to facilitate information-driven drug design for developing best- and first-in-class drugs.

SiCortex

Series A in 2004
SiCortex is the first company to engineer high-productivity computers from the silicon up. Instead of stacking large quantities of general computing chips together, they have carefully thought through the impact of every design element on the system, focusing attention on what truly drives performance.

TARIS BioMedical, Inc.

Venture Round in 2013
TARIS BioMedical, Inc., a therapeutically urology company, develops treatments for patients suffering from difficult-to-treat bladder diseases. It develops therapies for debilitating conditions, including bladder cancer and overactive bladder. The company was founded in 2008 and is based in Lexington, Massachusetts. As of December 20, 2019, TARIS BioMedical, Inc. operates as a subsidiary of Janssen Research & Development, LLC.

Automattic Inc.

Series B in 2008
Automattic is the company behind WordPress.com and WordPress.com VIP, the cloud version of WordPress. Automattic hosts and supports all WordPress.com sites ensuring that there is continuous and strategic development of the software available to its users. Automattic also supports WordPress.com VIP, a premium service designed for large-scale enterprises. WordPress.com VIP combines the benefits of WordPress.com and the ability to run custom code. In addition, WordPress.com VIP offers companies a robust CMS and 24/7 service.

Adimab

Series C in 2008
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Folx Health

Series A in 2021
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.

Sentillion

Series A in 1999
Sentillion, Inc. offers identity and access management technology solutions for caregivers in hospitals and healthcare organizations in North America and the United Kingdom. The company provides solutions for sign-on, user provisioning, clinical workstations, and virtualized remote access. The company offers expreSSO that delivers transparent single sign-on in existing workflows; Bridges, which provides a mechanism for interfacing to applications; and proVision that alters, disables, and terminates access to systems and applications. It also offers Vergence, which unifies single sign-on, single patient selection, and authentication services in clinical workstation solution that enables caregivers to access and navigate between the myriad of clinical and business applications. In addition, it offers vThere, which enables to manage clinicians and staff, such as medical transcriptionists, remote physicians, contractors, and temporarily displaced employees; and IdMPOWER that enables to accelerate the process of incorporating applications and information systems in the company's environment. The company offers implementation services, comprising project planning, installation, training, integrated testing, and deployment; and technical support services, including toll-free telephone support, trouble-shooting, and operational support. Sentillion, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Experience, Inc.

Venture Round in 2009
Experience, Inc. started in 1996 to help young adults learn from the experiences of others. More than a bank of resumes or a traditional job board, they help people understand their interests and aptitudes, and how they can apply their talents in the workforce. Their community at its core empowers the next generation workforce to access a world of possibilities.

Syros Pharmaceuticals

Series C in 2016
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Sesh Therapy Incorporated

Seed Round in 2020
Sesh is a mental health company providing access to group support via a mobile app. It offers a variety of sessions led by top mental health professionals for a fraction of the market price of a standard therapy appointment. The company was founded in 2020 and is headquartered in San Francisco, California.

GI Dynamics

Series C in 2009
GI Dynamics, Inc., a medical device company, designs, develops, manufactures, and markets medical devices for non-surgical approaches to treat type 2 diabetes and obesity. The company offers EndoBarrier, a medical device for the treatment of patients with type 2 diabetes and reduction of obesity. It serves health care providers and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Biolex Therapeutics

Series B in 2005
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

ICplanet

Venture Round in 2000
ICplanet a B2B Internet exchange connecting businesses with independent consultants.

Art.com

Series A in 2004
We exist so you can have the art you love. This means giving you easy access to incredible art images and top-notch craftsmanship. Because when you find art you love, you'll love your space more... and that's what it's all about. We work with passion to bring you the world's largest art collection. Whatever your interest, your décor style, your inspiration – we're sure to have that piece you can't live without. We believe art is dynamic, personal and connected to now, and the experience of buying and living with it should be too. From the moment you browse our site to the day your art is delivered, our team has one goal in mind: to delight you every step of the way.

Hydra Biosciences

Series C in 2008
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

Infinite Power Solutions

Venture Round in 2006
Infinite Power Solutions, Inc. (IPS), a U.S. based clean-technology company, is the global leader in developing, marketing and manufacturing solid-state, rechargeable thin-film micro-energy storage devices for a variety of micro-electronic applications. Founded in 2001, IPS is privately held with corporate headquarters and manufacturing facilities in the western suburbs of [Denver, CO](http://www.crunchbase.com/maps/search?range=10&geo=denver,+co). The company has completed the build-out of the world's first volume manufacturing facility dedicated to the production of its revolutionary thin-film micro-energy cell (MEC(TM)) products (often referred to as thin-film batteries). IPS has recently commenced pre-production activities at this state-of-the-art facility to address growing demand among customers in the wireless sensor, active RFID, powered smart card, medical device, consumer electronics, automotive and civil/military/aerospace markets

Localytics

Series B in 2012
Upland Localytics is a mobile app analytics and marketing platform. It gives companies the insights and tools they need to improve their mobile app acquisition, engagement, and retention efforts. It provides a family of cloud-based enterprise work management software applications for information technology, process excellence, finance, professional services, and marketing functions within organizations. The company's platform is used in more than 6,000 apps on more than 2 billion devices by companies such as Live Nation, HSN, Comcast, and The New York Times.
Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Auron Therapeutics

Seed Round in 2021
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Free & Clear

Venture Round in 2010
Free & Clear, Inc. provides phone-based tobacco treatment for employers, health plans, and government agencies. The company offers tobacco cessation program to employees and members of private employers, tobacco quit line services, and clinically proven method to stop smoking and using smokeless tobacco.
Seventh Sense Biosystems, Inc. develops a push-button blood collection device that enables patients to collect their own blood anywhere. It offers TAP that enables users to draw blood through a painless one-step process. Seventh Sense Biosystems, Inc. was formerly known as Newco LS 13, Inc. The company was founded in 2007 and is based in Medford, Massachusetts.

Kissmetrics

Series B in 2013
Kissmetrics offers behavioral analytics, segmentation, and email campaign automation all in one place. The company connect their experiment results to key business metrics they already track using Kissmetric, streamlines workflow by reviewing experiment results in their familiar Kissmetrics dashboard, and uncover new insights about your experiment using Kissmetrics capabilities Founded in 2008, Kissmetrics is run by a team of designers, developers, and entrepreneurs that are passionate about helping online businesses measure, grow, and monetize.

Asempra Technologies

Series B in 2006
As of May 1, 2009, Asempra Technologies, Inc. was acquired by Bakbone Software Inc. Asempra Technologies, Inc. provides instant recovery solutions for Windows applications and data. It offers Business Continuity Server, a recovery process that enables mid-market IT managers to restore Exchange, SQL, and Windows file servers; and Virtual On-Demand Recovery, a virtualized recovery and data protection solution. The company also provides disaster recovery, data deduplication, data replication, and data protection and recovery services. It has strategic partnerships with Hitachi Data Systems Corporation, Riverbed Technology, Dell EqualLogic, LeftHand Networks, HP, IBM, and Network Appliance. Asempra Technologies, Inc. was founded in 2003 and is headquartered in Santa Clara, California.

Esurg.com

Series A in 1999
Esurg.com, the most comprehensive and trusted online source for medical, surgical and pharmaceutical supplies and information. They designed Their Web site for the growing number of physician practices and clinics working outside traditional hospital settings — to give them an edge in the increasingly complex business of medicine.

JibJab Media Inc.

Series A in 2006
JibJab creates content and tools that help people be funny in their digital lives. From its flagship JibJab Ecards, Music Videos, and GIFs, to its new JibJab Camera app, the company has been pioneering new forms of digital fun since its founding by two brothers in a Brooklyn garage in 1999. Now based in Los Angeles, California, the studio is home to world-class artists, technologists and business people working hard in pursuit of their mission to make "billions of people happy."

Ultreo

Series C in 2007
Ultreo is a U.S.-based company that designs, develops, and manufactures power toothbrushes for consumers. The company combines patented ultrasound waveguide technology with sonic bristle action. It is headquartered in Redmond, Washington.

Veracode, Inc.

Series A in 2006
Veracode is the only independent provider of cloud-based application intelligence and security verification services. The Veracode platform provides the fastest, most comprehensive solution to improve the security of internally developed, purchased, or outsourced software applications and third-party components. It was founded in 2006 and headquartered in Burlington, Massachusetts.
KinDex Pharmaceuticals is a developer of novel therapeutics used to help patients suffering from metabolic disorders. It was established to focus on the discovery and development of molecules that improve women’s health and impact chronic disease. KinDex Pharmaceuticals is developing therapeutics that work through the Bitter Taste Receptors (TAS2Rs), a family of GPCR receptors that target inflammation and metabolic dysfunction.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

promoOrder.com

Venture Round in 2000
promoOrder.com provides business-to-business application services to the promotional products sector.

T2 Biosystems

Series D in 2011
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

US HealthVest, LLC

Series B in 2016
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Matrics

Series C in 2003
Matrics is a provider of RFID technology and visibility solutions for supply chain, asset management and security. Patented wireless tracking technologies provide users with the most reliable and cost-effective solutions to provide the comprehensive visibility of assets throughout an enterprise.

VKernel Corporation

Series B in 2009
VKernel was acquired by Quest Software in 2011. With Dell's acquistion of Quest in September 2012, VKernel is now a part of Dell. Founded in 2007, VKernel Corporation established itself as a leading provider of performance and capacity management products for VMware and Microsoft virtualized infrastructures. VKernel products simplify the complex and critical tasks of planning and predicting capacity utilization and performance bottlenecks. Used by over 50,000 system administrators, the products have proven their ability to maximize capacity utilization, reduce virtualization costs and improve application performance. Led by an experienced and proven management team, VKernel is well-positioned to address the growing demand and opportunity for performance and capacity management solutions for virtualized and cloud environments. The company has operations in the US and in Europe and sells its products directly or through a network of worldwide distribution and reseller partners.

Acceleron Pharma

Series B in 2006
Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

BlackArrow

Series A in 2004
BlackArrow is a provider of TV advertising and data solutions. Reaching over 37 million homes and trusted by the world’s largest service providers such as Comcast, Time Warner Cable, Virgin Media, Rogers Communications, and Bright House Networks, the company helps the pay-TV industry monetize video delivered to any screen at any time. Through a suite of integrated products, the company helps the pay-TV industry increase revenues by delivering more timely and efficient sales and marketing messages, extend TV services new screens, and gain real-time measurement and audience insights across multiple screens.

InsideSales.com, Inc.

Series D in 2017
XANT delivers the industry-leading sales engagement AI platform powered by Real DataTM. XANT provides solutions that accelerate revenue by enabling (sales) teams to build a better pipeline and close more deals. Our core differentiation stems from RealData that like modern AI apps such as WAZE, Netflix and Amazon use data though a collective that drives insights, scores and predictions across email, voice, LinkedIn, SMS interactions. Hundreds of customers across the globe including companies such as American Express, Cisco, John Hancock, and Pluralsight, trust XANT to drive productivity, visibility, and effectiveness in their prospect and customer interactions.

Microbia

Series E in 2006
Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Jibe

Series C in 2014
At Jibe, we create global recruiting software solutions to help the world’s leading companies identify, engage, and hire the best talent. Jibe's core technology is the Jibe Recruiting Cloud, a SaaS-based platform that enables leading companies to hire the best talent, regardless of their existing systems. Through this platform, Jibe provides a suite of products including personalized career sites and recruiting tools for sourcing, nurturing and marketing to candidates. Jibe currently serves the world's leading Fortune 500 companies, including Johnson & Johnson, FedEx, Marriott, and American Express. Elevated by strategic partnerships with Google and LinkedIn and backed by their expertise in recruiting technology, Jibe continues to be an innovative leader in the changing world of talent acquisition.

Acusphere

Funding Round in 2003
Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Archus Orthopedics

Series C in 2006
Archus Orthopedics is focused on the development of implants to treat a variety of spine disorders that result from degenerative changes in the facet joints. Archus Orthopedics offers Total Facet Arthroplasty System, a spinal implant that is designed for patients suffering from lumbar spinal stenosis. Archus Orthopedics was acquired by Facet Solutions in November 2009. Archus Orthopedics was founded in 2001 and is based in Redmond, Washington.

Convoq

Series C in 2006
Convoq was founded to develop a more effective solution for collaborating in real time. The company's founder and management team are experienced software entrepreneurs and technologists with proven records for delivering innovative, secure, and scalable products. They have built companies and commercial products and have been successful in deploying applications and infrastructure to some of the world's leading institutions.

Freenome, Inc.

Series C in 2020
Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Sentillion

Series C in 2001
Sentillion, Inc. offers identity and access management technology solutions for caregivers in hospitals and healthcare organizations in North America and the United Kingdom. The company provides solutions for sign-on, user provisioning, clinical workstations, and virtualized remote access. The company offers expreSSO that delivers transparent single sign-on in existing workflows; Bridges, which provides a mechanism for interfacing to applications; and proVision that alters, disables, and terminates access to systems and applications. It also offers Vergence, which unifies single sign-on, single patient selection, and authentication services in clinical workstation solution that enables caregivers to access and navigate between the myriad of clinical and business applications. In addition, it offers vThere, which enables to manage clinicians and staff, such as medical transcriptionists, remote physicians, contractors, and temporarily displaced employees; and IdMPOWER that enables to accelerate the process of incorporating applications and information systems in the company's environment. The company offers implementation services, comprising project planning, installation, training, integrated testing, and deployment; and technical support services, including toll-free telephone support, trouble-shooting, and operational support. Sentillion, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.

Boxever

Series A in 2014
Boxever is the Customer Intelligence Cloud for marketers. It connects all of your customer, product and operational data, putting your customer at the center of your business and enabling true 1:1 personalization on a level you’ve never seen before. This results in lower acquisition costs, accelerated conversion rates, improved customer engagement and higher lifetime value. Using artificial intelligence, it acts as the “brain” within your CRM-tech ecosystem, taking in all data about the customer - including behavioural and transactional - deciding what should happen next and executing that action through the most appropriate channels - in real time, as it happens.

Ocular Therapeutix

Series C in 2009
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Formspring

Series A in 2010
Formspring is a startup that helps people find out more about each other by sharing interesting & personal responses. Formspring encourages people to get to know each other better in a simple and fun way. It starts by directly asking people original questions in anticipation of their entertaining or revealing responses. Responses can range from straightforward to surprising and can lead to understanding something more about the people you know or find interesting. Whether you are curious to know more about a college you are applying to, the movies your friend likes, or the stories of someone you respect, on Formspring, you can have fun, share insights, and relate to one another in a new way.

Sonrai Security Inc.

Series A in 2019
Sonrai Security delivers an enterprise identity and data governance platform for AWS, Azure, Google Cloud, and Kubernetes. The Sonrai Dig platform is built on a sophisticated graph that identifies and monitors every possible relationship between identities and data that exists inside an organization’s public cloud. Dig’s Governance Automation Engine automates workflow, remediation, and prevention capabilities across cloud and security teams to ensure end-to-end security. The company was founded in 2017 and is headquartered in New York.

Notarize

Series C in 2020
Notarize operates an online notary public service that enables users to connect with a commissioned online eNotary public by live video call. It offers Notarize, a software service that allows clients to complete the notarization process remotely and entirely online; Notarize for business, a platform for organizations and developers to collect notarized documents; and Notarize for Mortgage, a platform that digitizes the closing process with technology to coordinate lenders, title companies, and borrowers online. Notarize's electronic notary public service is offered to customers via iOS, Android and web Pat Kinsel founded the company as 16 Pins in May 2015. Notarize has its headquarters in Boston in Massachusetts.

Folx Health

Venture Round in 2020
Folx Health is a digital health services platform that builds a medical service marketplace tailored towards the queer community. It combines access to a specialized network of queer and trans clinicians with a tailored focus on clinical offerings that are typically marginalized in traditional health settings. The startup focuses on providing patients gender-affirming hormone therapy, sexual health, and family creation services. Other services include erectile dysfunction treatment, PrEP, and STI testing. The company was founded by Agneta Breitenstein in 2019 in Boston, Massachusets.

RetireOne

Venture Round in 2013
RetireOne is the leading, independent platform for fee-based insurance solutions. With offerings from multiple “A” rated companies, RIAs may access this fiduciary marketplace at no additional cost to them or their clients. Tallying over $1 billion of retirement savings and income investments under advisement, RetireOne continues to grow in its mission to provide advisors and their clients valuable retirement solutions that are simple to use, easy to understand, and delivered with outstanding service.

ice

Venture Round in 2008
Ice.com, Inc. owns and operates an online jewelry shopping Website. It offers earrings, bracelets, necklaces, and watches; diamond rings, gemstone rings, pearl rings, gold rings, silver rings, alt metal rings, and wedding rings; and wedding jewelry and fragrances, as well as jewelry for women, men, and children. The company was formerly known as BuyJewel.com, Inc. and changed its name to Ice.com, Inc. in May 2000. Ice.com, Inc. was founded in 1999 and is based in Austin, Texas. Ice.com, Inc. operates as a subsidiary of CSC Generation, Inc.

eSupportNow

Venture Round in 2000
Founded in 1998, eSupportNow (www.esupportnow.com) is located in Boston, Massachusetts. The company maintains an infrastructure specifically designed to accommodate the necessary operations, staffing and technology required to provide online customer service and sales support. eSN is a spin-off of The Cross Country Group which, for more than 25 years, has been a recognized leader in outsourced customer service solutions that enable companies to develop, foster and expand their relationships with existing and prospective customers.

Phreesia

Series C in 2009
Innovative point-of-service platform drives efficiency and profitability throughout your organization

Quantcast

Series C in 2010
Quantcast processes real-time data at the intersection of commerce and culture, providing useful, actionable insights for brands and publishers. Through Quantcast Measure, we have unlocked the data generated by more than 100 million digital destinations, helping publishers and creators understand and grow their businesses in ways never before possible. With Quantcast Advertise, adaptive modeling and intelligent machines are utilized to help thousands of marketers around the world find and interact with customers anywhere they connect to the digital world. Our more than 600 employees are driven by the potential for big data to radically improve everyone’s connected experiences and transform the way we all make sense of the world.

Q1 Labs

Series C in 2004
Qradar, a network security management solution that includes log, threat and compliance management

Morphic Holding, Inc.

Series A in 2016
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

Allux Medical

Series C in 2010
Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Infinite Power Solutions

Series B in 2008
Infinite Power Solutions, Inc. (IPS), a U.S. based clean-technology company, is the global leader in developing, marketing and manufacturing solid-state, rechargeable thin-film micro-energy storage devices for a variety of micro-electronic applications. Founded in 2001, IPS is privately held with corporate headquarters and manufacturing facilities in the western suburbs of [Denver, CO](http://www.crunchbase.com/maps/search?range=10&geo=denver,+co). The company has completed the build-out of the world's first volume manufacturing facility dedicated to the production of its revolutionary thin-film micro-energy cell (MEC(TM)) products (often referred to as thin-film batteries). IPS has recently commenced pre-production activities at this state-of-the-art facility to address growing demand among customers in the wireless sensor, active RFID, powered smart card, medical device, consumer electronics, automotive and civil/military/aerospace markets

BlackArrow

Series C in 2010
BlackArrow is a provider of TV advertising and data solutions. Reaching over 37 million homes and trusted by the world’s largest service providers such as Comcast, Time Warner Cable, Virgin Media, Rogers Communications, and Bright House Networks, the company helps the pay-TV industry monetize video delivered to any screen at any time. Through a suite of integrated products, the company helps the pay-TV industry increase revenues by delivering more timely and efficient sales and marketing messages, extend TV services new screens, and gain real-time measurement and audience insights across multiple screens.

Visterra

Series C in 2017
Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Thing Labs

Series A in 2008
Thing Labs builds web-based software that makes it easy to create, share, explore and enjoy content. Founded by Jason Shellen, a former Googler who worked on Blogger and co-created Google Reader, Thing Labs is the company behind Brizzly and Plinky.

Africa Healthcare Network

Series A in 2019
Africa Healthcare Network (“AHN”) has established the first dialysis chain across Sub-Saharan Africa, providing high-quality, life-saving dialysis at affordable cost. AHN brings world-class technical expertise combined with developing world practical operating experience to a region in dire need of quality dialysis treatment. Dialysis is a life-saving treatment for patients with Acute Kidney Injury (AKI) and End-Stage Renal Disease (ESRD). The few hospitals that provide treatment operate centers that are slowly deteriorating while charging prohibitive prices. Additionally, the lack of trained professionals and limited capital investment in care for non-communicable diseases in Sub-Saharan Africa, dialysis centers are few and far between, causing patients to endure the high costs for travel to receive care. Those who cannot afford the costs of treatment and travel are resigned to death. Chronic Kidney Disease (CKD) and AKI are on the rise in the region due to strong epidemiologic factors, including increased urbanization leading to lifestyle diseases, other non-communicable diseases, HIV and other infections and toxins. Utilizing our network of executives/partners, we will secure high-quality equipment and train professionals to provide superior care. Our ability to source lowest cost consumables, operational efficiency and scale, will allow us to lower the cost to patients. The net result is increased access, higher quality and lower cost to patients, while maintaining profitability. AHN operates in Rwanda, Tanzania and Kenya.

CatchFree

Series A in 2011
CatchFree.com makes it easy to find and compare the best free online solutions for your specific need. By organizing feedback from active users, CatchFree helps you assess how each product performs your needed task.

Navitor Pharmaceuticals

Series A in 2014
Navitor Pharmaceuticals is a developer of novel medicines designed to target specific nutrient-sensing proteins that selectively regulate mTORC1 activity to treat diseases. The company's medicines selectively modulate the activity of mTORC1, a master regulator of cell growth and metabolism, and unlock the therapeutic potential of the mTOR pathway by targeting the amino acid and other nutrient sensors that selectively regulate the activity of mTORC1, enabling healthcare practitioners to address a wide range of metabolic, neurodegenerative, autoimmune and musculoskeletal diseases. It was founded in 2009 and headquartered in Cambridge, Massachusetts.

Ucentric Systems

Venture Round in 2003
Ucentric Systems is a provider of home media networking software for digital home. Its modular digital home software suite includes media centers/gateways, multi-television DVR, and home music software solutions.

Arsenal Medical

Series B in 2007
Arsenal Medical, Inc., a platform technology company, develops polymer based foams and fibers for the treatment of vascular diseases. It develops in-situ forming foams to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair. The company also provides AxioCore, a core-sheath nanofiber and microfiber technology constructed from known biomaterials, which is used for cell integration and tissue regeneration enabling controlled delivery of a range of biologics and therapeutics. Arsenal Medical, Inc. was founded in 2005 and is based in Watertown, Massachusetts.

turntable.fm

Series A in 2011
Turntable.fm is a project of [Seth Goldstein](http://www.crunchbase.com/person/seth-goldstein) and [Billy Chasen](http://www.crunchbase.com/person/billy-chasen), the two guys who brought us [Stickybits](http://www.crunchbase.com/organization/stickybits). Users in each dance room has an avatar and can chat with each other. Users can create their own playlist and get up in the DJ booth to battle it out. Turntable.fm a social music platform that encourages hanging out with people and discovering music. If a DJ is playing a song you like, you can add it to your playlist, buy it on iTunes, find it on Last.fm, or launch Spotify. In November 2013, Turntable announced they would be shutting down turntable.fm to focus on their live events platform.

Metacrine

Series B in 2017
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Selecta Biosciences

Series C in 2010
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

BIND Therapeutics

Series C in 2010
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

WHI Solution

Venture Round in 2006
WHI was founded as Wrenchead.com in March of 1999, to create a B2C ecommerce channel for traditional wholesalers. Word quickly spread from one satisfied user to another and by February of 2000 they had over 1 million visitors per month. During that time they also began to license their technology to enable wholesale distributors to do business online. That business began to grow dramatically and they knew they had to make a choice. They sold the B2C business to focus on providing better ebusiness solutions for distributors.

WHI Solution

Venture Round in 2000
WHI was founded as Wrenchead.com in March of 1999, to create a B2C ecommerce channel for traditional wholesalers. Word quickly spread from one satisfied user to another and by February of 2000 they had over 1 million visitors per month. During that time they also began to license their technology to enable wholesale distributors to do business online. That business began to grow dramatically and they knew they had to make a choice. They sold the B2C business to focus on providing better ebusiness solutions for distributors.

Midstream Technologies

Series C in 2002
MidStream Technologies(TM) has developed the world's first dedicated streaming appliance. One box can deliver 16,000 simultaneous broadband streams with unprecedented scalability. A multiple box configuration provides built-in load balancing, failover reliability and the power to deliver millions of concurrent streams. MidStream servers can support every popular streaming format simultaneously & allow for software and appliance upgrades in the field, extending hardware longevity and promoting cost savings.

mValent

Venture Round in 2005
[mValent](http://www.mvalent.com/) is a provider of application configuration management solutions. In February of 2009, they were acquired by [Oracle](http://www.crunchbase.com/organization/oracle).

BIND Therapeutics

Series A in 2007
They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverse effects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines.

Iora Health

Series B in 2013
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Respicardia, Inc.

Series C in 2010
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

T2 Biosystems

Series E in 2013
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

Kallyope

Series B in 2018
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

ChipIn

Series B in 2008
ChipIn is an online fundraising service that includes a widget and application developer for businesses. They still aim and focus on empowering and engaging a wide and distributed network of supporters particularly those with brilliant and outstanding ideas in fundraising. This is expected to apply mainly to major and large-scale funding campaigns that take into consideration all or many players in this niche. What’s more, all this is just a rough guideline of what they intend to do. Any useful suggestions of how to relaunch this platform are indeed welcome. At the end of the day, the bottom line remains that they still believe that any idea that is worth poring over is still worth seeing the light of day, as long as it is to the greater benefit of humanity.

Paratek

Venture Round in 2008
Paratek designs and manufactures adaptive RF front-end component solutions for mobile wireless applications. Paratek's product offerings for multi-mode and multi-band operation cover three major applications : Adaptive Impedance Matching Modules (AIMM), Broadband filters and pre-selectors for RF front-end devices, Radio Antenna Frequency Tuners (RAFTâ„¢). Paratek works collaboratively with customers. That means they listen closely to what your needs and milestones are, and then work to adapt their technology to yours. Applications differ, but the beauty of their adaptive approach is that they can easily fine-tune solutions based around certain operating bands, frequency ranges, and industry protocols. If your need is slightly different from the next, that's where they shine!

Partnerware

Series B in 2000
Partnerware maximizes speed-to-market™ for channel-focused companies with the leading B2B Partner Relationship Management (PRM) solution, delivering measurable channel results in Internet time. As a multi-channel sales approach becomes critical in delivering value-added solutions to the marketplace, the need for PRM has grown dramatically. Partnerware provides distinct benefits for companies looking to leverage the power of indirect - Faster channel execution (from channel recruiting to product launches) - Measurable results from partner programs, channel marketing funds, and partner sales efforts - Increased market responsiveness to leap frog and stay ahead of competition - Easy implementation by deploying Web-based Partner Relationship Management solutions in Internet time

Cerulean Pharma

Series B in 2009
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

aTyr Pharma, Inc.

Series D in 2013
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Kala Pharmaceuticals

Series A in 2013
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Recurly

Series C in 2019
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.

T2 Biosystems

Series C in 2010
T2 Biosystems is a private company developing a next-generation medical diagnostic platform that will enable rapid and accurate diagnostic tests of all types on a single, easy to use instrument. The proprietary technology combines nanotechnology and miniaturized magnetic resonance (MR) technology and eliminates the need for costly and time consuming sample preparation.

BalconyTV

Series A in 2012
BalconyTV was founded in June 2006 when three Dublin friends began filming an internet show from their apartment balcony on Dame Street in Dublin. BalconyTV began filming local bands who wanted to appear on the music show. Today BalconyTV is produced in 43 cities around the world. Over 8000 videos have been archived and these have been watched over 40 million times.

KenSci Inc.

Series B in 2019
KenSci's machine learning powered risk prediction platform helps healthcare providers and payers intervene early by identifying clinical, financial and operational risk to save costs and lives. KenSci's platform is engineered to ingest, transform and integrate healthcare data across clinical, claims, and patient-generated sources. With a library of pre-built models and modular solutions, KenSci's machine learning platform to integrates into existing workflows allowing health systems to better identify utilization, variation and improve hospital operations. With Explainable AI models for healthcare, KenSci is making risk-based prediction more efficient and accountable.

Thirty Madison, Inc.

Series B in 2020
Thirty Madison, Inc., a digital health company, owns and operates web-based platforms for patients with hair loss, migraines, and other chronic conditions. It offers Keeps, a subscription-based online marketplace for over-the-counter medications for men’s hair loss prevention. The company also provides Cove, an online doctor visit and prescription service to treat migraine. In addition, it offers Evens that helps to treat acid reflux. Thirty Madison, Inc. was incorporated in 2016 and is headquartered in Astoria, New York.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory diseases, and organ transplants. Pandion’s approach has the potential to more effectively induce and sustain response and remission in patients with many autoimmune and inflammatory conditions. They aim to shift the paradigm and create a new generation of drugs with transformative efficacy and improved safety.

Apnex Medical

Series A in 2007
Apnex Medical, Inc. manufactures and markets medical devices such as implants for the treatment of obstructive sleep apnea. Apnex Medical, Inc. was incorporated in 2006 and is based in Saint Paul, Minnesota.

EXOS

Series A in 2006
EXOS Physical Therapy and Sports Medicine, LLC provides athletic training and physical therapy services. The company was formerly known as D1 Sports Medicine, LLC and changed its name to EXOS Physical Therapy and Sports Medicine, LLC in August 2017. EXOS Physical Therapy and Sports Medicine, LLC was incorporated in 2010 and is based in Franklin, Tennessee. As of August 25, 2017, EXOS Physical Therapy and Sports Medicine, LLC operates as a subsidiary of Exos Partners, LLC.

Recurly

Seed Round in 2010
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.

Silicon Optix

Series B in 2003
Silicon Optix is a fabless semiconductor company, supplier of warping integrated circuit (IC) technology – eWARP™. eWARP digital distortion correction allows manufacturers to complement optics with sophisticated electronics imaging in order to achieve superior system designs and add new compelling features to products while reducing cost and complexity of optical systems. Silicon Optix has the only mainstream geometry processing IC in volume production to date. Over seven years of research and development invested in IC design, system design and optics have given Silicon Optix the expertise to be the leader in this emerging technology with large market opportunities.

Lob

Series B in 2017
Lob automates direct mail for modern businesses. More than 7,000 companies use Lob’s APIs to move faster and create new growth opportunities. Lob’s APIs dramatically reduce mail processing time, reclaiming thousands of hours and improving data quality. One in four households in the U.S. have received mail generated through Lob’s platform. Headquartered in San Francisco, Lob is backed by leading investors including Y Combinator, First Round Capital and Polaris Partners.

TechTarget, Inc.

Series C in 2004
TechTarget provides purchase intent-driven marketing and sales services for enterprise technology companies. The company attracts technology buyers researching companies’ information technology needs, with quality editorial content across more than 140 highly targeted technology-specific websites. TechTarget creates the purchase intent insights that fuel effective marketing and sales activities for clients by understanding tech buyer content consumption. TechTarget helps more than 1,300 tech companies accomplish sustainable pipeline impact. It was founded on 1999 and is headquartered in Newton, Massachusetts.

1366 Technologies Inc.

Series A in 2008
1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

PhyFlex Networks

Series A in 2001
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Heavy

Series E in 2006
Heavy is a platform for the most sought-after news and information. Through its flagship website, Heavy.com, and Spanish-language platform, AhoraMismo.com, readers benefit from rapid, unbiased reporting to access the content they want in real time. Heavy.com was founded by entrepreneurs Simon Assaad and David Carson in 1999 as a video-focused entertainment site aimed primarily at young men. It rebooted in 2012 as a news site and today receives nearly 25 million readers a month. Assaad continues to serve as CEO. Heavy’s content is driven by data around the stories, trends and products people search for the most. The editorial team is made up of a mix of veteran reporters with independent journalists, who work on an editorial agenda built for quality, efficiency and speed. Heavy’s rapid original reporting and user-friendly formats, such as its “5 Fast Facts” posts, offer facts about trending topics in real time. Heavy has also been recognized for reporting well ahead of mainstream news sites and is often sourced in editorial reporting. AhoraMismo is a Spanish-language platform that equips U.S. Hispanics with news, information and other resources to help them navigate daily life. From entertainment and sports news to educational content on health, wellness and women’s issues, to analysis of important issues such as immigration, politics and financial planning, AhoraMismo arms its readers with tools to be more informed and improve their quality of life.

Neuronetics

Series E in 2011
Neuronetics is focused on developing non-invasive therapies for psychiatric and neurological disorders using MRI-strength magnetic field pulses. They are the first and only company to have a non-systemic and non-invasive depression treatment cleared by the FDA for patients who have not benefited from prior antidepressant treatment. The company was founded in 2003 and is based in Malvern, Pennsylvania.

Ultreo

Series C in 2007
Ultreo is a U.S.-based company that designs, develops, and manufactures power toothbrushes for consumers. The company combines patented ultrasound waveguide technology with sonic bristle action. It is headquartered in Redmond, Washington.

FloQast

Series C in 2020
FloQast builds cloud-based software that helps manage accounting departments by centralizing the workflow, assigning tasks, maintaining supporting documentation and automating reconciliations.

SpineZone

Series A in 2021
Developed by spine specialists, the SpineZone Method relieves long-term back and neck injuries without resorting to invasive procedures

Hydra Biosciences

Series B in 2004
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.

WeatherBug

Series B in 2004
WeatherBug is a leading collection of weather apps, delivering local, national and international weather information via all web and mobile platforms.

IconOVir Bio

Series A in 2021
IconOVir Bio is a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer.

Turbine

Series A in 2003
Turbine creates and operates online games. It is one of the largest privately-held online gaming studios in North America. Turbine's online games include The Lord of the Rings Online, Shadows of Angmar, Dungeons & Dragons Online, Stormreach and Asheron's Call.

StoreRunner

Venture Round in 2000
In late 1998, StoreRunner.com launched as one of the first online shopping sites on the Web, offering a wide selection of products and services from the most trusted retailers, with technologies enabling users to shop online or in their own neighborhoods. In early 1999, CBS committed over $100 million in promotional support to StoreRunner in exchange for an equity stake in the business. This investment allowed StoreRunner to promote its brand across all CBS' television, radio, outdoor and interactive media properties, rapidly accelerating StoreRunner's appeal to shoppers and merchants. In May of 2000, after months of consumer research and testing, StoreRunner re-launched its own branded site with an entirely new look and feel, improved navigation, advanced search functionality, enhanced data feed capabilities for large retailers and catalogers, a suite of e-Commerce-enabling tools for small-to-mid size businesses, and an expanded database of over 1 million products in over 8,000 different categories.

SiOnyx, Inc.

Series B in 2010
SiOnyx, Inc. commercializes a semiconductor process that enhances the infrared sensitivity of silicon-based photonics. It focuses on the performance of light sensing devices for security, defense, consumer, industrial, medical, and automotive applications. The company offers XQE CMOS image sensors that provide night vision, biometrics, eye-tracking, and natural human interface; and HD action video cameras. SiOnyx, Inc. was incorporated in 2005 and is based in Beverly, Massachusetts.

Arsanis

Series D in 2017
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Arsanis

Series B in 2013
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

TopFloor, Inc.

Venture Round in 2012
TopFloor is a place to discover and shop for products you'll love. We take the hassle out and put the fun into your shopping experience. Our hand picked, constantly updated selection of unique fashions, accessories, gifts, and home and family items makes finding new products easy. Entertaining videos make learning about our products fun. Sharing products and sales on your social networks gets your friends in on the action. And then of course there are our limited-time sales that give you the opportunity to buy the great stuff you see on TopFloor at special, friends-only prices. We're more than a place to shop, we're a place where shopping becomes a part of your life.

ICplanet

Series A in 1999
ICplanet a B2B Internet exchange connecting businesses with independent consultants.

Cerulean Pharma

Series A in 2007
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

Convoq

Series B in 2003
Convoq was founded to develop a more effective solution for collaborating in real time. The company's founder and management team are experienced software entrepreneurs and technologists with proven records for delivering innovative, secure, and scalable products. They have built companies and commercial products and have been successful in deploying applications and infrastructure to some of the world's leading institutions.

ClearSky Data, Inc.

Venture Round in 2018
ClearSky Data’s global storage network simplifies the entire data lifecycle and delivers enterprise storage as a fully managed service. Its storage is designed for business agility. ClearSky simplifies enterprise storage by providing an SLA-based managed service across the global network. The company's patent-pending Smart Tiered Caching continually categorizes data and places it in the right cache layer (hot, warm, cold) based on evolving usage requirements and customer policies. Customers simply scale as needed, using the ClearSky dashboard to add unlimited capacity with a few clicks. All data can be moved across the ClearSky network to meet a variety of use cases including data center migration, load balancing, expansion into new regions, or disaster recovery. ClearSky has partnered with major public clouds to place hot and warm cache copies at the cloud edge. The result: customers get low-latency access to cloud instances, providing a new cost-effective option to run their most demanding workloads. The total cost of ownership (TCO) of storing data using the ClearSky service is about 1/3 the cost of managing it in a company’s data center on physical storage arrays. By leveraging the architecture and building redundancy into all cache layers and network paths, ClearSky is able to provide an enterprise-class service with guaranteed high availability. Industry-leading security technologies and best practices ensure that customer data is always protected and isolated from the moment it enters the ClearSky network. Customers simply plug into the ClearSky service to get the storage they need, when and where they need it, with the security, scalability, and resilience that a business depends on.

Morphic Holding, Inc.

Series B in 2018
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.

Archivas

Series B in 2004
Archivas, Inc. software lets customers store, protect and manage fixed-content data in the most open and operationally efficient online environment available on the market today, in order to meet both internal governance, as well as external compliance regulations. The Archivas Cluster (ArC) simultaneously addresses the need for immediate access to archive data while lowering the total cost of ownership.

PhyFlex Networks

Series B in 2002
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.
Primmune Therapeutics, Inc., a biotechnology company, develops small molecule orally administered toll-like receptor 7 (TLR7) agonist to stimulate innate immunity in cancer immunotherapy. It offers TLR7 agonist for systemic activation of innate immunity. The company’s TLR7 is an agonist for acute and chronic viral infection. The company was founded in 2017 and is based in San Diego, California.

Phreesia

Series B in 2007
Innovative point-of-service platform drives efficiency and profitability throughout your organization

Impinj, Inc.

Series C in 2004
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

SiCortex

Series B in 2006
SiCortex is the first company to engineer high-productivity computers from the silicon up. Instead of stacking large quantities of general computing chips together, they have carefully thought through the impact of every design element on the system, focusing attention on what truly drives performance.

480 Biomedical

Series C in 2015
480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery (SFA). Its lead product, SFA scaffold, is a proprietary scaffold and delivery system for use in treating peripheral arterial disease in the SFA. The company was founded in 2011 and is based in Watertown, Massachusetts.

Gossamer Bio, Inc.

Series B in 2018
Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

Imprivata

Series C in 2008
FairWarning’s platform helps healthcare and enterprise organizations comply with regulations, protect sensitive data, and prevent insider threats. A driving force in building the patient privacy monitoring industry, FairWarning expanded to support other highly regulated industries and applications like Salesforce to help customers easily interpret, investigate and detect anomalous user access or behavior. The company combines advanced technologies including machine learning and AI with best practices and managed services to provide the highest level of security to organizations across the globe. Safeguarding over 350 enterprise customers globally, including 35% of U.S. health systems, FairWarning is trusted to protect organizations’ sensitive data while creating a culture of privacy.

GlycoFi Inc.

Series C in 2005
GlycoFi is a biotech firm that develops biotherapeutics based on the glycan optimization technology. The firm aims to develop its own pipeline of therapeutic proteins and team with other drug-makers to develop products. GlycoFi has developed a protein manufacturing process using yeast-based glycolysation where the resulting proteins can be used in drug development. GlycoFi was incorporated in 2000 and is based in Lebanon, New Hampshire. As of June 6, 2006, GlycoFi, Inc. operates as a subsidiary of Merck & Co. Inc.

Kala Pharmaceuticals

Series C in 2016
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high, sustained local drug concentrations with reduced systemic exposure and are delivered in a patient friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept, while establishing R&D collaborations with select partners to improve products in their pipelines.

Bluetrain.io

Seed Round in 2013
Bluetrain.io is a cloud CMS that is transforming how developers build and manage responsive websites by bundling all core CMS functions in a massively scaleable utility. Our platform enables developers to create professional enterprise websites much faster than ever before, and without custom Php or .Net coding. Unlike older CMS platforms like WordPress, SiteCore and Drupal, Bluetrain.io enables developers, designers, information architects to collaboratively build websites on the cloud, while enabling marketers to maintain and update responsive websites across mobile, tablet and desktop devices.

Lyndra Inc

Series A in 2017
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.

Acceleron Pharma

Venture Round in 2010
Biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics

Ember Technologies

Venture Round in 2009
Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Arsanis

Series A in 2011
As of March 13, 2019, Arsanis, Inc. was acquired by X4 Pharmaceuticals Inc., in a reverse merger transaction. Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address infectious diseases in the United States. The company engages in the development of ASN500, a mAb that is in preclinical development targeting respiratory syncytial virus (RSV), a virus that can cause respiratory tract infections in young children and elderly, and immunocompromised patients. Its pipeline also comprises mAbs targeting various serious bacterial and viral pathogens, including Staphylococcus aureus and RSV. In addition, the company’s preclinical stage Gram-negative mAb programs include ASN300 for Klebsiella pneumoniae and ASN200 for Escherichia coli. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Pulmatrix

Series B in 2011
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Adimab

Series A in 2007
Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements.

Iora Health

Series F in 2020
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Selecta Biosciences

Private Equity Round in 2014
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

Kronos Bio, Inc.

Private Equity Round in 2020
Kronos Bio focuses on the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. It develops therapies that modulate historically undruggable targets. The company leverages deep capabilities in high-throughput small-molecule microarrays (SMM), targeted protein degradation, and cancer biology in order to identify potent and selective compounds against transcription factors and other central drivers of oncogenic signaling.

Avaki

Series A in 2001
AVAKI provides grid solutions which enable organizations not only to manage but to leverage the explosion in data and applications, within and across enterprises. A grid is a heterogeneous network which appears and functions as one large operating environment. AVAKI grid solutions can be broken down conceptually into two major categories: compute grids and data grids. AVAKI 2.0 delivers the functionality of each, as well as integrated solutions. Any or all aspects of the software can be implemented, depending on an organization's needs.

Follica, Inc.

Series B in 2008
Follica, Inc. develops a treatment system for hair loss in adult humans. It offers an in-office treatment proprietary device that disrupts the skin and creates new hair follicles; and at-home treatment system that delivers compounds directly to the scalp for a daily routine. Follica, Inc. was incorporated in 2005 and is based in Boston, Massachusetts. Follica, Inc. operates as a subsidiary of PureTech Health plc.

Nomad Health

Series B in 2018
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.

PhyFlex Networks

Private Equity Round in 2007
PhyFlex Networks is a business services software and broadband access company that creates new business models for cable operators through its True Broadband solution. True Broadband includes a comprehensive software suite for the creation, provisioning, and management of end-to-end broadband services dynamically and on demand.

Genocea Biosciences

Series B in 2009
Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, to profile patient’s CD4+ and CD8+ T cell immune responses to potential target or antigen in that patient's tumor. It develops immuno-oncology programs, such as GEN-009, an adjuvanted neoantigen peptide vaccine candidate, which is in the phase I/IIa clinical trial; GEN-011, a neoantigen adoptive T cell therapy program; and GEN-010, a neoantigen vaccine program. Genocea Biosciences, Inc. was founded in 2006 and is based in Cambridge, Massachusetts.

1366 Technologies Inc.

Series B in 2010
1366 Technologies Inc. develops, manufactures, and supplies silicon wafers. It offers 3D direct wafers and silicon solar wafers. 1366 Technologies Inc. has strategic partnerships with Hanwha Q CELLS Malaysia Sdn. Bhd. and Hanwha Q CELLS Co., Ltd. The company was founded in 2007 and is based in Bedford, Massachusetts. It has locations in Shanghai, China; and Mumbai, India.

ByHeart

Series A in 2020
ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at the forefront of immune, microbiome, cognitive, and digestive health. The company was founded in 2016 and is headquartered in New York.

Aepona Limited

Series C in 2007
Aepona Ltd. provides application-led products and services to telecommunications operators worldwide. Its Universal Service Platform allows service creation and implementation to be carried out within the service network from underlying network resources. Aepona, Ltd. serves customers in Europe, North America, and South East Asia. The company was founded in 1999 and is headquartered in Belfast, United Kingdom. Aepona Ltd. is a former subsidiary of ApiON Ltd.

Biolex Therapeutics

Series C in 2007
Biolex is a clinical-stage biopharmaceutical company that uses their patented LEX SystemSM to develop hard-to-make therapeutic proteins and monoclonal antibodies that have been optimized to enhance their efficacy and potency. The LEX System is a technology that genetically transforms the aquatic plant Lemna to enable the production of biologic product candidates. Their main product aims at treating those afflicted with Hepatitis C.

Sprout

Series B in 2008
Sprout helps creative professionals build rich media HTML5 ads simply. Their AdVine platform is integrated with leading mobile ad networks and publishers. Anyone can now build rich HTML5 mobile ads once then run everywhere. Fully integrated with the leading ad servers and social networks, Sprout campaigns can run anywhere your consumers spend time online. Sprout customers include Disney, Warner Bros., HBO, Federated Media, Intel, Technorati, Toyota, and MTV. Funded by Polaris Venture Partners, Sprout is based in Honolulu, HI and San Francisco, CA. To learn more, visit sproutinc.com.

Falkonry

Seed Round in 2017
Falkonry Inc. develops a machine learning software that updates condition recognition capabilities resulting from new data and expert feedback. It offers products, such as Falkonry LRS that multivariates time series data to discover patterns, predict critical events, and explain behaviors in operations; and Falkonry Edge Analyzer, a portable engine enabling predictive models to be deployed on edge devices. The company serves Global Fortune 2000 industrial companies. Falkonry Inc. was founded in 2012 and is based in Sunnyvale, California.
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Follica, Inc.

Series B in 2010
Follica, Inc. develops a treatment system for hair loss in adult humans. It offers an in-office treatment proprietary device that disrupts the skin and creates new hair follicles; and at-home treatment system that delivers compounds directly to the scalp for a daily routine. Follica, Inc. was incorporated in 2005 and is based in Boston, Massachusetts. Follica, Inc. operates as a subsidiary of PureTech Health plc.

BlackArrow

Series B in 2007
BlackArrow is a provider of TV advertising and data solutions. Reaching over 37 million homes and trusted by the world’s largest service providers such as Comcast, Time Warner Cable, Virgin Media, Rogers Communications, and Bright House Networks, the company helps the pay-TV industry monetize video delivered to any screen at any time. Through a suite of integrated products, the company helps the pay-TV industry increase revenues by delivering more timely and efficient sales and marketing messages, extend TV services new screens, and gain real-time measurement and audience insights across multiple screens.

BlackArrow

Series B in 2006
BlackArrow is a provider of TV advertising and data solutions. Reaching over 37 million homes and trusted by the world’s largest service providers such as Comcast, Time Warner Cable, Virgin Media, Rogers Communications, and Bright House Networks, the company helps the pay-TV industry monetize video delivered to any screen at any time. Through a suite of integrated products, the company helps the pay-TV industry increase revenues by delivering more timely and efficient sales and marketing messages, extend TV services new screens, and gain real-time measurement and audience insights across multiple screens.

Turbine

Series C in 2008
Turbine creates and operates online games. It is one of the largest privately-held online gaming studios in North America. Turbine's online games include The Lord of the Rings Online, Shadows of Angmar, Dungeons & Dragons Online, Stormreach and Asheron's Call.

Roundbox

Series C in 2008
Roundbox is a provider of mobile broadcast software solutions for mobile operators and handset manufacturers. Their products enable mobile operators to provide consumers innovative services that take advantage of next generation broadcast networks.

KSQ Therapeutics, Inc.

Series B in 2017
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Q1 Labs

Series B in 2003
Qradar, a network security management solution that includes log, threat and compliance management

Morphic Holding, Inc.

Seed Round in 2016
Morphic Therapeutic is a biotechnology company developing a new generation of oral integrin therapies. Drawing on discoveries made in the lab of Scientific Founder Tim Springer, Morphic was created in 2015 with co-founders Polaris Partners, T.A. Springer and Schrödinger, Inc., along with ShangPharma Investment Group.

Allux Medical

Series B in 2007
Allux Medical develops medical devices for the treatment of hyper-reactive airway mucosa. The company, formerly known as MedInvent, Inc., is based in Menlo Park, California. Shut down on Feb, 2009.

Genomics Medicine Ireland

Series A in 2016
Genomics Medicine Ireland is an Irish life sciences company leading a large-scale research study across Ireland looking at the human genome to examine the relationship between genetics, health and disease.

Mazlo

Venture Round in 2015
Mazlo helps you unlock your potential for personal and professional growth with just ten minutes a day of real-life practice supported by two weeks of personalized 1:1 coaching. Every Mazlo program includes: - A two-week curriculum designed by a prominent subject-matter expert - Daily ten-minute exercises for learning, practice, reflection, and real-life application - Private coaching via personal video message or written message

Pervasis Therapeutics

Series B in 2005
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Adcade

Series A in 2013
Adcade provides mobile and tablet media solutions for advertisers, publishers, and developers to achieve their marketing or monetization goals. The company was founded in 2012 and is based in New York, New York.

Accordant Health Services

Venture Round in 2000
Accordant provides its program members with healthcare advice. The service focuses on delivering support for patients with rare, chronic diseases. Its care management solutions comprise of tools and resources of professionals in the healthcare sector. The service also delivers care management services for rare diseases which include health plans, employers, and third party administrators. Accordant is a subsidiary of CVS Caremark. It was founded by Steve Schelhammer and is headquartered in Greensboro, North Carolina.

InsideSales.com, Inc.

Series C in 2014
XANT delivers the industry-leading sales engagement AI platform powered by Real DataTM. XANT provides solutions that accelerate revenue by enabling (sales) teams to build a better pipeline and close more deals. Our core differentiation stems from RealData that like modern AI apps such as WAZE, Netflix and Amazon use data though a collective that drives insights, scores and predictions across email, voice, LinkedIn, SMS interactions. Hundreds of customers across the globe including companies such as American Express, Cisco, John Hancock, and Pluralsight, trust XANT to drive productivity, visibility, and effectiveness in their prospect and customer interactions.
Quintessent Communications

OpenReach

Series B in 2000
OpenReach is a provider of virtual private networking (VPN) software and services.

Adnexus

Series B in 2006
Engages in the development of Adnectins biologics and medicines in the United States

Ocular Therapeutix

Series D in 2011
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Ember Technologies

Series B in 2002
Ember is a design-led temperature control brand whose mission is to revolutionize the way people eat, drink and live. Founded by inventor and serial entrepreneur Clay Alexander, Ember designs and develops patented technology and products that disrupt industries across healthcare, wellness, consumer products and more. From inventing the world’s first temperature control smart mug, to revolutionizing the cold chain for temperature sensitive medicines, Ember is creating a multidisciplinary temperature control platform that brings precision temperature control to your fingertips.

Cerulean Pharma

Series C in 2010
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

Ocular Therapeutix

Series C in 2011
Ocular Therapeutix, Inc. engages in the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. Its products include ReSure Adherent Ocular Bandage, a synthetic ocular bandage for ophthalmic surgery; ReSure Sealant, a synthetic and biocompatible hydrogel that creates a temporary, soft, and lubricious surface barrier to protect clear corneal incisions in the immediate post-operative period; and prostaglandin analog punctum plugs that are hydrogel-based punctum plug depots to deliver prostaglandin analogs to treat glaucoma.

Pervasis Therapeutics

Seed Round in 2004
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Lyndra Inc

Series B in 2019
Lyndra Therapeutics is reinventing medicines to make daily pills a thing of the past, replacing them with its oral, ultra-long-acting, sustained-release therapies. Administering and conveniently distributing medicines in weekly or longer-term doses – including using polypill approaches – will improve safety, efficacy, and adherence to maximize global health impact and lower overall healthcare costs.

Nomad Health

Series C in 2019
Nomad Health, Inc. operates an online marketplace that enables users to find freelance and permanent clinical work in the United States. Its market place enables doctors to search for jobs by location, pay rate, medical facility, and more; and healthcare facilities to find doctors. The company was incorporated in 2015 and is based in New York, New York.

GreenFuel

Series C in 2008
GreenFuel Technologies Corporation (GFT) was a startup that developed a process of growing algae using emissions from fossil fuel combustion and solar panels, mainly to produce biofuel from algae.

Athenix

Series C in 2006
Athenix is a leader in agricultural and industrial biotechnology. They have built the infrastructure necessary to discover new genes and to develop them into products that meet real customer needs.

Wantful

Series A in 2012
Wantful, a San Francisco, CA- and NYC-based gift-giving service. Founded in 2011 by by designer and serial entrepreneur John Poisson, CEO, the company also expects to make a number of key hires in both its San Francisco and New York City offices in order to grow its engineering, merchandising and operations teams.

Sirtris Pharmaceuticals

Series B in 2005
[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Roundbox

Series B in 2006
Roundbox is a provider of mobile broadcast software solutions for mobile operators and handset manufacturers. Their products enable mobile operators to provide consumers innovative services that take advantage of next generation broadcast networks.

Voysis

Series A in 2017
Voysis is an Ireland-based AI startup. Voysis works specifically in the speech recognition domain and develops tech that makes it easier for digital voice assistants to understand a user’s natural language. Voysis believes that voice will soon be the first point of contact between ‘man’ and machine. Voysis believes that voice driven natural language interfaces will change the way people interact with consumer and enterprise facing applications by creating more intuitive, efficient, and personalized experiences. Voysis is a voice AI platform that will play a key role in bringing about this change. Voysis' mission is to be the de-facto platform to enable any business to rapidly ‘stand up’ deep domain, brand-specific, intelligent voice systems enabling rich, natural language interactions between their brands and users.

Tempo Pharmaceuticals

Series B in 2008
Tempo Pharmaceuticals is a biotechnology company based in Madrid, Spain.

Dataupia Corporation

Series B in 2007
Dataupia Corporation provides a data warehouse appliance. It offers Satori Server, a server, storage, and optimization software packaged as a single appliance. The company also provides customer support, consulting, and training services. It serves telecommunications, retail, eCommerce, health sciences, and financial services markets. Dataupia Corporation was founded in 2005 and is based in Cambridge, Massachusetts.

Boxever

Series B in 2016
Boxever is the Customer Intelligence Cloud for marketers. It connects all of your customer, product and operational data, putting your customer at the center of your business and enabling true 1:1 personalization on a level you’ve never seen before. This results in lower acquisition costs, accelerated conversion rates, improved customer engagement and higher lifetime value. Using artificial intelligence, it acts as the “brain” within your CRM-tech ecosystem, taking in all data about the customer - including behavioural and transactional - deciding what should happen next and executing that action through the most appropriate channels - in real time, as it happens.

Cardiac Dimensions

Series B in 2002
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Solace Pharmaceuticals

Series A in 2007
Solace Pharmaceuticals, a Boston based drug company focused on therapeutics for chronic pain.

Aepona Limited

Series C in 2010
Aepona Ltd. provides application-led products and services to telecommunications operators worldwide. Its Universal Service Platform allows service creation and implementation to be carried out within the service network from underlying network resources. Aepona, Ltd. serves customers in Europe, North America, and South East Asia. The company was founded in 1999 and is headquartered in Belfast, United Kingdom. Aepona Ltd. is a former subsidiary of ApiON Ltd.

Microbia

Series F in 2007
Microbia an industrial biotechnology company, engages in the development, production, and commercialization of specialty ingredients and biomaterials utilizing fermentation technology. Its products include carotenoids, specialty ingredients, biopolymers, and other biomaterials. The company has a strategic alliance with Tate & Lyle Investments, Ltd. to develop and commercialize fermentation-derived renewable ingredients.

Logentries

Seed Round in 2012
Logentries is a SaaS-delivered log management and analytics service, developed to make machine-generated log data easily accessible to developers, operations, and business analytics customers. While traditional log management and analytics solutions require advanced technical skills to use, and are costly to set-up, Logentries provides an accessible alternative for managing huge amounts of data, visualizing insights that matter, and sharing that information across the business. With more than 20,000 users in over 100 countries, Logentries is processing billions of events everyday.

Promedior

Series D in 2012
Promedior, Inc. a clinical-stage biotechnology company, develops therapeutics to treat rare fibrotic diseases, such as myelofibrosis and idiopathic pulmonary fibrosis; and retinal fibrovascular diseases, such as age related macular degeneration and diabetic retinopathy. Its portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein (rhPTX-2) formulated for intravenous injection; and PRM-167, a variant of rhPTX-2 developed for intravitreal delivery in retinal fibrovascular diseases. Promedior, Inc. was formerly known as Fibrotix, Inc. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of February 13, 2020, Promedior, Inc. operates as a subsidiary of Roche Holding AG.

Nanosys

Series A in 2002
Nanosys, Inc. develops and delivers quantum dot technology for high definition viewing experience for the display industry. It offers Quantum Dot Concentrate material; quantum dot nanomaterials; and Quantum Dot Enhancement film to industrial supply chain partners. Its products are used in tablets, televisions, smartphones, and other consumer electronics applications. Nanosys, Inc. was incorporated in 2001 and is based in Milpitas, California.

One Health Company

Series A in 2020
The One Health Company is a social impact company that brings precision medicine, used in humans, to dogs with cancer. It started by offering dogs with cancer access to cutting edge human clinical trials at no cost. Then, they created FidoCure directly for veterinarians and pet parents to offer treatment options to more dogs across the country. The company built partnerships with the world's top cancer researchers and a network of 111 of the best veterinary hospitals.

Adnexus

Series A in 2003
Engages in the development of Adnectins biologics and medicines in the United States
Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
Faraday Pharmaceuticals is an early-stage therapeutics company focused on developing novel therapies to treat ischemia-reperfusion injury. It has in-licensed proprietary liquid formulations of reduced nonmetal gaseous elements developed in the lab of Dr. Mark Roth at the Fred Hutchinson Cancer Center. The company was founded in 2014 and is located in Seattle, Washington.

Cerulean Pharma

Series B in 2008
Cerulean Pharma Inc. is a privately-held biopharmaceutical company focused on the development of novel nanotechnology-based therapeutics in the areas of oncology, cardiovascular, autoimmune and inflammatory diseases. The Company has assembled a world-class management team, board of directors and scientific advisory board that collectively have a significant track record of business building, product development and scientific breakthroughs from companies and institutions such as Cubist, GlaxoSmithKline, Merck, Millennium Pharmaceuticals, Inc., Pfizer, Wyeth, the Massachusetts Institute of Technology, Harvard Medical School, MD Anderson, Fox Chase Cancer Center and the Arizona Health Center.

Promedior

Series A in 2006
Promedior, Inc. a clinical-stage biotechnology company, develops therapeutics to treat rare fibrotic diseases, such as myelofibrosis and idiopathic pulmonary fibrosis; and retinal fibrovascular diseases, such as age related macular degeneration and diabetic retinopathy. Its portfolio includes PRM-151, a recombinant form of human pentaxin-2 protein (rhPTX-2) formulated for intravenous injection; and PRM-167, a variant of rhPTX-2 developed for intravitreal delivery in retinal fibrovascular diseases. Promedior, Inc. was formerly known as Fibrotix, Inc. The company was incorporated in 2006 and is based in Lexington, Massachusetts. As of February 13, 2020, Promedior, Inc. operates as a subsidiary of Roche Holding AG.

Baxter Planning Systems, Inc.

Corporate Round in 2017
Baxter pioneered the development of Web-based solutions to meet the unique demands of inventory planning across complex, global supply chains in the service parts, high tech and healthcare industries. Their software Prophet™, is a suite of integrated forecasting and planning applications that enables their clients to achieve industry-leading customer service levels while significantly controlling inventory and increasing profitability. Baxter also offers inventory planning consultation with an experienced team who can help you lower your inventory costs while improving your customer's satisfaction.

Cardiac Dimensions

Series C in 2004
Cardiac Dimensions, Inc., a medical device company, engages in the development of minimally invasive treatment modalities to address heart failure and related cardiovascular conditions. The company develops Carillon Mitral Contour System, a permanent implant for the treatment of functional mitral regurgitation. The company was incorporated in 2000 and is based in Kirkland, Washington with additional operations in Sydney, Australia and Offenbach, Germany.

Localytics

Series C in 2014
Upland Localytics is a mobile app analytics and marketing platform. It gives companies the insights and tools they need to improve their mobile app acquisition, engagement, and retention efforts. It provides a family of cloud-based enterprise work management software applications for information technology, process excellence, finance, professional services, and marketing functions within organizations. The company's platform is used in more than 6,000 apps on more than 2 billion devices by companies such as Live Nation, HSN, Comcast, and The New York Times.

Suneva Medical, Inc.

Series B in 2014
Suneva Medical, Inc. is a privately held medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. It provides a novel and differentiated aesthetic products for the dermatology, plastic, and cosmetic surgery markets. The company’s flagship brand, Bellafill is the only dermal filler on the market with five-year safety and efficacy data, and the only dermal filler approved for the correction of facial acne scars. The Suneva Medical product portfolio focuses on compelling, differentiated products that deliver high patient satisfaction and represent a significant business opportunity to its practice partners. The company was founded in 2015 and headquartered in San Diego, California.

Arsenal Medical

Venture Round in 2015
Arsenal Medical, Inc., a platform technology company, develops polymer based foams and fibers for the treatment of vascular diseases. It develops in-situ forming foams to provide local therapy for acute hemorrhage and other critical clinical conditions, including vascular injury and repair. The company also provides AxioCore, a core-sheath nanofiber and microfiber technology constructed from known biomaterials, which is used for cell integration and tissue regeneration enabling controlled delivery of a range of biologics and therapeutics. Arsenal Medical, Inc. was founded in 2005 and is based in Watertown, Massachusetts.

Heavy

Series D in 2006
Heavy is a platform for the most sought-after news and information. Through its flagship website, Heavy.com, and Spanish-language platform, AhoraMismo.com, readers benefit from rapid, unbiased reporting to access the content they want in real time. Heavy.com was founded by entrepreneurs Simon Assaad and David Carson in 1999 as a video-focused entertainment site aimed primarily at young men. It rebooted in 2012 as a news site and today receives nearly 25 million readers a month. Assaad continues to serve as CEO. Heavy’s content is driven by data around the stories, trends and products people search for the most. The editorial team is made up of a mix of veteran reporters with independent journalists, who work on an editorial agenda built for quality, efficiency and speed. Heavy’s rapid original reporting and user-friendly formats, such as its “5 Fast Facts” posts, offer facts about trending topics in real time. Heavy has also been recognized for reporting well ahead of mainstream news sites and is often sourced in editorial reporting. AhoraMismo is a Spanish-language platform that equips U.S. Hispanics with news, information and other resources to help them navigate daily life. From entertainment and sports news to educational content on health, wellness and women’s issues, to analysis of important issues such as immigration, politics and financial planning, AhoraMismo arms its readers with tools to be more informed and improve their quality of life.

KSQ Therapeutics, Inc.

Series C in 2018
KSQ Therapeutics is pioneering High-Confidence Drug Development: a fundamentally new approach to R&D where the majority of the de-risking work is done prior to the generation of therapeutic drug candidates. Powered by our proprietary CRISPRomics™ drug discovery engine, their team has elucidated the function that each human gene plays in multiple diseases, providing a unique and more comprehensive understanding of disease biology. The quality of these insights enables their scientists to rapidly identify and validate high-confidence, patient-tailored, novel drug targets and then focus their collective efforts on the development of medicines with the greatest potential to impact the lives of patients. KSQ has initiated a pipeline of preclinical discovery programs and was founded in 2015.

Metacrine

Series C in 2018
Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Pulmatrix

Post in 2015
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.

Respicardia, Inc.

Series B in 2008
Respicardia (formerly Cardiac Concepts) is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve respiratory rhythm management and cardiovascular health. The first product, the remedē® System, is an implantable stimulation device that is designed to restore a more normal breathing pattern during sleep for patients with central sleep apnea. Respicardia® is committed to improving cardiovascular health…one breath at a time™.

CodeRyte

Series C in 2006
CodeRyte is the premier provider of computer-assisted coding and clinical data extraction solutions for the healthcare industry. Their sophisticated technology streamlines the coding process and identifies clinically relevant information from medical records. Their clients secure their rightful reimbursement, enhance compliance and efficiency through computer-assisted coding. CodeRyte's data extraction solutions analyze the language of physician narratives and elevate previously undiscovered data for critical treatment and business decisions. Many of the nation's top physician practices, billing companies and academic medical centers rely on CodeRyte as the centerpiece of their coding and data mining operations.

Selecta Biosciences

Series E in 2015
Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles. It was founded in 2008 and is headquartered in Watertown, Massachusetts.

Mintera

Series B in 2005
Mintera Corporation develops and markets high speed optical transmission systems. It offers MI 40000XS that provides a transport subsystem for carriers, enterprises, educational institutions, and government agencies. The company also provides fiber-optic transport systems that enable deployment of optical transport in metro-core, regional, long-haul, and ultra long-haul networks. Mintera Corporation was founded in 2000 and is based in Acton, Massachusetts.

Hangout Industries

Series B in 2009
Hangout is building the next generation in social gaming by combining the powerful community of social networks with the rich immersion and engaging casual game-play of a 3D virtual world. Play Games, Go Shopping, Throw Parties for Causes in Hangout Teen girls (and later guys) create their own personalized avatars, play casual mini-games, go shopping, throw parties for their friends, or just hangout. Playing games earns money for fashionable looks, new moves on the dance floor, or money to give to charity. At launch, players will be able to begin building their fashion empire as they level up to become a top fashion designer. Soon they can also aspire to become a dance master or the ultimate chef in order to throw the party of a lifetime, all in the name of a real charity of their choice. Hangout is about having fun with friends, meeting new people, and making a difference! Hangout Uniquely Integrates Social Games with a Virtual World Each game te publish seamlessly plugs into the same virtual world, so players keep their avatars, possessions, and status from game to game. The integrated publishing approach results in improved cross-promotion and better player retention and monetization.

NetRate Systems, Inc.

Venture Round in 2018
NetRate Systems, Inc., a privately held company located in Okemos, Michigan, provides insurance processing solutions designed to simplify the submission, underwriting, rate, quote, issue, and reporting processes inherent in commercial insurance distribution. They have been delivering insurance processing technology solutions since 1998. Their U.S.-based team of professionals incorporates the latest technologies and industry standards to deliver and maintain high quality, easy-to-use, low-maintenance solutions that integrate into your business processes. They are committed to delivering their solutions with the highest levels of customer service, professionalism, and integrity. Their rating and policy issuance solutions include support for all major ISO® lines of business, nationwide. NetRate also offers custom development of all lines of business, including custom Professional Liability. The NetRate solutions can be deployed as hosted, cloud-based web services, Windows applications, or hosted, web-based portals. NetRate Systems also provides integration of third-party data sources and services to speed up the quoting and subsequent reporting processes.

GI Dynamics

Series B in 2004
GI Dynamics, Inc., a medical device company, designs, develops, manufactures, and markets medical devices for non-surgical approaches to treat type 2 diabetes and obesity. The company offers EndoBarrier, a medical device for the treatment of patients with type 2 diabetes and reduction of obesity. It serves health care providers and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

OM1, Inc.

Series B in 2018
OM1 (formerly Better Outcomes) is a digital health company focused on solving the problem of determining and understanding the true results of healthcare. We believe that a value-based healthcare system requires a much more complete view of patient outcomes than has been available until now. We leverage a state-of-the-art technology platform, a world-class team of scientists, clinical experts and software engineers, and a committed network of organizations to create a new standard for health outcomes information.

3PLex.com

Series B in 2000
3PLex.com improves productivity for all segments of the transportation industry by combining the real-world expertise of 3PL companies with the efficiencies of Internet logistics. Unlike logistics Web sites that seek to cut out 3PLs by linking shippers and carriers directly, 3PLex.com provides 3PLs with immediate, low-cost access to online load-matching and automation tools in order to realize efficiency gains. By bringing 3PLs, carriers and shippers together online, 3PLex.com helps its member companies improve productivity and grow their businesses by moving a greater volume of goods more cheaply, easily and reliably. Founded in 1999, 3PLex.com is based in Cambridge, Massachusetts. 3PLex is now owned by IBM.

TechTarget, Inc.

Series B in 2004
TechTarget provides purchase intent-driven marketing and sales services for enterprise technology companies. The company attracts technology buyers researching companies’ information technology needs, with quality editorial content across more than 140 highly targeted technology-specific websites. TechTarget creates the purchase intent insights that fuel effective marketing and sales activities for clients by understanding tech buyer content consumption. TechTarget helps more than 1,300 tech companies accomplish sustainable pipeline impact. It was founded on 1999 and is headquartered in Newton, Massachusetts.

Sockeye Networks

Series A in 2001
Sockeye Networks is a provider of intelligent routing services. Sockeye Networks enables businesses to intelligently optimize their Internet connectivity, improving network performance, efficiency and visibility. Sockeye Networks developed the industry's first intelligent route optimization service to solve the problems of poor performance, high costs, and limited visibility. The Sockeye Networks GlobalRoute service is the first route optimization solution to integrate local and global Internet traffic conditions to provide real-time network visibility and optimization for multihomed environments. GlobalRoute continuously monitors and analyzes multiple Internet connections in order to select the optimal paths for IP traffic flows. This ensures that customers' network performance and cost goals are realized, enabling them to confidently depend on the Internet for mission-critical applications.

Transoma Medical

Series D in 2008
Transoma Medicalis a provider of implantable wireless diagnostic systems for patients with chronic cardiovascular disease and for biomedical research. The company’s products include small wireless sensors that transmit information from inside the body to a receiver via radio-frequency waves, as well as unique software to condense the data these devices provide into meaningful information.

US HealthVest, LLC

Series A in 2013
US HealthVest is an innovative behavioral healthcare firm that has redefined the psychiatric hospital space. De novo strategies and acquisitions of operating facilities with unrealized potential are the core of the US HealthVest business model. Each facility is structured to offer multiple service lines in order to serve the needs of specific patient population groups. The senior management team of US HealthVest has successfully built psychiatric hospital businesses which were acquired by public companies. Ascend Health was founded by Richard Kresch, M.D. in 2005 and was one of the largest private psychiatric hospital providers with nine freestanding facilities and nearly 900 beds. Ascend Health was sold to Universal Health Services (NYSE: UHS) in 2012. The predecessor company, Heartland Health Developments, also focused on psychiatric care and was sold to Psychiatric Solutions in 2004.

Montis Biosciences

Seed Round in 2020
Montis Biosciences develops immune-oncology therapeutics targeting the intersection between vascular dysfunction and immune suppression to treat solid tumors. It creates a target screening and assay platform to develop targets modulating interactions between tumor endothelial cells and perivascular macrophages. The company was founded in 2020 and is based in Meise, Belgium.

Recurly

Series A in 2012
Recurly, Inc. develops and provides enterprise-class subscription management solutions to optimize and automate revenue growth for businesses worldwide. Its subscription management solution allows users to speed time-to-value, maximize revenue, boost developer productivity, gain actionable insights, and ensure security and compliance. The company provides subscription management solutions, deep payments expertise, and data-driven billing intelligence to optimize subscription revenue growth for businesses. Its subscription management and billing platform manage subscription revenues for companies in digital media, streaming, publishing, SaaS, consumer goods, and professional services industries. The company was incorporated in 2009 and is based in San Francisco, California. It has additional offices in Boulder, Colorado and New Orleans, Louisiana.

Dyno Therapeutics Inc.

Seed Round in 2020
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Earth Networks

Series B in 2004
Earth Networks, Inc. operates weather observation and lightning networks in the United States, Europe, and internationally. It gathers, analyzes, and distributes environmental observations from around the world to help promote a better understanding of the planet and its atmosphere. The company’s products and services include forecasting, LCD weather display, GIS data services, data feed, meteorological, online weather, plume modeling, lightning network, weather stations, dangerous thunderstorm alerts, weather monitoring and alerting, atmospheric data, and risk notification systems; and weather cameras. It serves various industries, such as agriculture, education, energy and utilities, media, sports and recreation, electric power, and transportation; and federal, state, and local emergency response and government agencies, clubs, societies, consumers, and organizations. The company was formerly known as AWS Convergence Technologies, Inc. and changed its name to Earth Networks, Inc. in January 2011. The company was founded in 1993 and is based in Germantown, Maryland.

GI Dynamics

Series A in 2003
GI Dynamics, Inc., a medical device company, designs, develops, manufactures, and markets medical devices for non-surgical approaches to treat type 2 diabetes and obesity. The company offers EndoBarrier, a medical device for the treatment of patients with type 2 diabetes and reduction of obesity. It serves health care providers and third-party distributors. The company sells its products primarily in Europe, the Middle East, the Asia Pacific, and South America. GI Dynamics, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

BridgePort Networks

Series B in 2004
Fixed-mobile convergence applications for telecommunications service providers

Proficiency

Series C in 2001
Proficiency, Inc. provides product knowledge integration and CAD interoperability solutions that enable manufacturers and suppliers to share product knowledge from various engineering and manufacturing environments. Its solutions include product knowledge migration, which delivers a process of technology and methodology that meets migration needs; and supplier delivery solutions to original equipment manufacturers or higher tier suppliers. The company’s products also include Collaboration Gateway V7.0, which enables the transfer of the product knowledge between CAD systems that include geometry, features, sketches, manufacturing info, metadata, assembly information, and drawings in the conversion process; and Completion Wizard, which provides an interactive method of completing the process. In addition, it offers CAD translation services, such as geometry-only, product knowledge, and associative drawing translations; consulting services, such as migration strategy, supplier delivery strategy, and process integration consulting; and implementation services, such as training, customer support, and customer specific developments. The company serves various companies in the automotive, aerospace and defense, and heavy machinery industries. Proficiency, Inc. was founded in 1998 and is based in Marlborough, Massachusetts. As of July 1, 2009, Proficiency, Inc. operates as a subsidiary of ITI TranscenData.

Hangout Industries

Series A in 2007
Hangout is building the next generation in social gaming by combining the powerful community of social networks with the rich immersion and engaging casual game-play of a 3D virtual world. Play Games, Go Shopping, Throw Parties for Causes in Hangout Teen girls (and later guys) create their own personalized avatars, play casual mini-games, go shopping, throw parties for their friends, or just hangout. Playing games earns money for fashionable looks, new moves on the dance floor, or money to give to charity. At launch, players will be able to begin building their fashion empire as they level up to become a top fashion designer. Soon they can also aspire to become a dance master or the ultimate chef in order to throw the party of a lifetime, all in the name of a real charity of their choice. Hangout is about having fun with friends, meeting new people, and making a difference! Hangout Uniquely Integrates Social Games with a Virtual World Each game te publish seamlessly plugs into the same virtual world, so players keep their avatars, possessions, and status from game to game. The integrated publishing approach results in improved cross-promotion and better player retention and monetization.

Ucentric Systems

Series A in 2000
Ucentric Systems is a provider of home media networking software for digital home. Its modular digital home software suite includes media centers/gateways, multi-television DVR, and home music software solutions.

aTyr Pharma, Inc.

Series B in 2007
aTyr Pharma is a biotherapeutics company that discovers and develops protein biologics for human therapeutics. The company has established a dominant intellectual property estate surrounding Physiocrine-based compositions and potential therapeutic applications. aTyr’s key programs are focused on immunomodulation disorders in the areas of inflammation and immunity and are in preclinical development. The company's primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. The privately held biotech was founded by The Scripps Research Institute Professor Paul Schimmel, a leading aminoacyl tRNA synthetase scientist, and is backed by top life sciences investors Alta Partners, Cardinal Partners, Domain Associates and Polaris Ventures.

Impinj, Inc.

Venture Round in 2012
Impinj is a provider of RAIN RFID solutions that deliver Item Intelligence to retail, pharmaceutical, healthcare, food and beverage, and many other industries. We enable the Internet of Things to identify, locate and authenticate billions of items, and our Item Intelligence platform comprises the most comprehensive and widely adopted RAIN RFID product portfolio in the world. For more information about Impinj, visit www.impinj.com.

Incentive Systems

Series D in 2001
"Incentive Systems is the industry pioneer and leader in the Enterprise Incentive Management marketplace, which is predicted by AMR to grow rapidly, reaching an annual market size of $2 billion in software revenue alone in 2005, and is also the first software company in which Thomas Weisel Capital Partners, LP made a private equity investment," said Alan Menkes, partner, co-director of private equity for Thomas Weisel Partners LLC. "Since their initial investment, Incentive Systems has continued to deliver industry-leading technology and services to the marketplace, and has seen tremendous growth in demand for its solutions, among both public and private organizations, across several industries. The company is on track to reach its goal of profitability in the near-term, and they were delighted by the oppornity to lead this round and further strengthen their partnership with Incentive Systems."

Archus Orthopedics

Series B in 2003
Archus Orthopedics is focused on the development of implants to treat a variety of spine disorders that result from degenerative changes in the facet joints. Archus Orthopedics offers Total Facet Arthroplasty System, a spinal implant that is designed for patients suffering from lumbar spinal stenosis. Archus Orthopedics was acquired by Facet Solutions in November 2009. Archus Orthopedics was founded in 2001 and is based in Redmond, Washington.

Pervasis Therapeutics

Venture Round in 2008
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Ascend Health

Series B in 2007
Ascend Health Corporation is a behavioral healthcare provider, offering a full range of inpatient and day hospital services to children, adolescents, adults and seniors. They focus on personal choice and specialized care. Their facilities provide high quality care by working closely to integrate their services with the healthcare system in each local community.

Kallyope

Series C in 2020
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the gut informs our brains about our well-being, metabolism, and nutritional state. The gut-brain axis—the communication highway between our gut and our brain—offers an unprecedented opportunity to access and influence brain centers involved in fundamental human processes. An understanding of the biology mediated by the gut and gut-brain circuits will change the way we think about food, nutrition, and human physiology

Pervasis Therapeutics

Series A in 2004
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.

Automattic Inc.

Series A in 2005
Automattic is the company behind WordPress.com and WordPress.com VIP, the cloud version of WordPress. Automattic hosts and supports all WordPress.com sites ensuring that there is continuous and strategic development of the software available to its users. Automattic also supports WordPress.com VIP, a premium service designed for large-scale enterprises. WordPress.com VIP combines the benefits of WordPress.com and the ability to run custom code. In addition, WordPress.com VIP offers companies a robust CMS and 24/7 service.

Qstream

Series B in 2016
Qstream, Inc. develops a software as a service based mobile sales acceleration software for managing and measuring the human side of sales acceleration. It serves companies in technology, financial services, and life sciences sectors. Qstream, Inc. was formerly known as Spaced Education, Inc. The company was incorporated in 2008 and is based in Burlington, Massachusetts with engineering facilities in Dublin, Ireland; and Hood River, Oregon. It has a sales headquarters in Maidenhead, United Kingdom and an office in San Francisco.

ShoeDazzle.com, Inc.

Series B in 2010
ShoeDazzle is a fashion subscription service that brings a personalized boutique experience to an online platform. ShoeDazzle offers VIP Elite Membership for $39.95 each month which converts into rollover “VIP Credits” that members can spend or save for later. Every month, the company debuts a new selection of exclusive and brand-name shoes, handbags and more, including a custom online showroom, curated to each client’s individual style preferences. Rachel Zoe serves as the company’s Chief Stylist.

Radico

Series C in 2019
Simon Data is the enterprise Customer Data Platform (CDP) that empowers brands to deliver data-driven, personalized customer experiences anywhere.The platform leverages enterprise-scale big data and machine learning to power customer communications in any channel. Simon’s unique approach allows brands to develop and deliver incredible personalization capabilities without needing to build and maintain massive bespoke data infrastructure. At Simon, our goal is to improve and optimize customer experiences by making the entire process, experimentation through analysis, a data-driven one.

Drizly, Inc.

Series A in 2015
Drizly is an e-commerce alcohol marketplace and the best way to shop beer, wine, and spirits. With the speed and convenience of on-demand delivery and shipping, Drizly partners with retailers in 235 markets to offer consumers of legal drinking age unrivaled selection and a transparent, personalized shopping experience. Backed by world-class institutional investors, Drizly partners with retailers to bring their shelves online, helping them to reach new customers, tap into key market and customer insights, and diversify their business to grow sales.

Iora Health

Series C in 2015
Iora Health, Inc. operates a healthcare system that provides primary care services in the United States. It operates primary care practice for college employees and their adult dependents. The company also provides educational offerings, including group visits to help patients stay on track with their health. Iora Health, Inc. was founded in 2010 and is based in Boston, Massachusetts.

Pulmatrix

Series A in 2009
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies for the treatment, prevention, and transmission control of infectious and progressive respiratory diseases. It offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company was founded in 2003 and is based in Lexington, Massachusetts.